0001144204-17-042023.txt : 20170810 0001144204-17-042023.hdr.sgml : 20170810 20170810152505 ACCESSION NUMBER: 0001144204-17-042023 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170810 DATE AS OF CHANGE: 20170810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55723 FILM NUMBER: 171021229 BUSINESS ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 BUSINESS PHONE: 858-605-9055 MAIL ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 10-Q 1 v472618_10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2017

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission file number: 000-55723

GUARDION HEALTH SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

47-4428421

(State or other jurisdiction

of incorporation or

organization)

(Address and telephone number of
principal executive offices)

(I.R.S. Employer

Identification No.)

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

(Address and telephone number of principal executive offices)

Not applicable

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	¨	Smaller reporting company	x
(Do not check if a smaller reporting company)		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨ Yes x No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

As of August 10, 2017, there were outstanding 25,641,551 shares of the issuer’s common stock, $0.001 par value. Registrant’s common stock is not yet publicly traded.

TABLE OF CONTENTS

		Page No.
PART I – FINANCIAL INFORMATION

ITEM 1.	CONDENSED FINANCIAL STATEMENTS	4

	Balance Sheets – As of June 30, 2017 (Unaudited) and December 31, 2016	4

	Statements of Operations (Unaudited) – Three and Six Months Ended June 30, 2017 and June 30, 2016	5

	Statement of Stockholders’ Deficiency (Unaudited) – Six Months Ended June 30, 2017	6

	Statements of Cash Flows (Unaudited) – Six Months Ended June 30, 2017 and June 30, 2016	7

	Notes to Financial Statements (Unaudited)	8

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	17

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	24

ITEM 4.	CONTROLS AND PROCEDURES	24

PART II – OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	25

ITEM 1A.	RISK FACTORS	25

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	25

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	26

ITEM 4.	MINE SAFETY DISCLOSURES	26

ITEM 5.	OTHER INFORMATION	26

ITEM 6.	EXHIBITS	26

SIGNATURES		27

Introductory Comment

Throughout this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” “our company,” “Guardion,” the “Company” and the “Registrant” refer to Guardion Health Sciences, Inc.

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements. These statements relate to future events or future predictions, including events or predictions relating to our future financial performance, and are based on current expectations, estimates, forecasts and projections about us, our future performance, our beliefs and management’s assumptions. They are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “feel,” “confident,” “estimate,” “intend,” “predict,” “forecast,” “potential” or “continue” or the negative of such terms or other variations on these words or comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks described under “Risk Factors” that may cause the Company’s or its industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In addition to the risks described in Risk Factors, important factors to consider and evaluate in such forward-looking statements include: (i) general economic conditions and changes in the external competitive market factors which might impact the Company’s results of operations; (ii) unanticipated working capital or other cash requirements including those created by the failure of the Company to adequately anticipate the costs associated with acquisitions and other critical activities; (iii) changes in the Company’s corporate strategy or an inability to execute its strategy due to unanticipated changes; and (iv) the failure of the Company to complete any or all of the transactions described herein on the terms currently contemplated. As a result of these risks and uncertainties, many of which are described in greater detail in the Risk Factors discussion in our Annual Report on Form 10-K for the year ended December 31, 2016 (“Form 10-K”) and in the other documents we file from time to time with the SEC, there can be no assurance that the forward-looking statements contained in this Report will in fact transpire.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company will not update or revise the forward-looking statements except to the extent required by applicable law.

PART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED FINANCIAL STATEMENTS

Guardion Health Sciences, Inc.

Condensed Balance Sheets

	June 30,			December 31,
	2017			2016
	(Unaudited)
Assets

Current assets
Cash	$	297,536		$	62,520
Accounts receivable		1,662			1,673
Inventories		108,303			43,999
Current portion of deposits and prepaid expenses		6,576			29,363

Total current assets		414,077			137,555

Deposits and prepaid expenses, less current portion		10,470			10,470
Property and equipment, net		88,188			114,020

Total assets	$	512,735		$	262,045

Liabilities and Stockholders’ Deficiency

Current liabilities
Accounts payable and accrued liabilities	$	413,907		$	356,467
Accrued expenses and deferred rent		14,667			88,290
Due to related parties		169,320			91,483
Convertible notes payable		45,811			44,323
Promissory notes payable		125,314			10,251
Promissory notes payable related party		-			16,805

Total current liabilities		769,019			607,619

Commitments and contingencies

Stockholders’ Deficiency

Series A preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,705,154 and 1,705,154 shares issued and outstanding at June 30, 2017 and December 31, 2016		1,705			1,705
Series B preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,100,000 issued and outstanding at June 30, 2017		1,100			-
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,634,751 and 25,046,438 shares issued and outstanding at June 30, 2017 and December 31, 2016		25,635			25,046
Additional paid-in capital		22,056,862			20,277,882
Accumulated deficit		(22,341,586	)		(20,650,207	)

Total stockholders’ deficiency		(256,284	)		(345,574	)

Total liabilities and stockholders’ deficiency	$	512,735		$	262,045

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statements of Operations

	Three Months Ended June 30,						Six Months Ended June 30,
	2017			2016			2017			2016
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenue	$	59,977		$	29,384		$	115,912		$	58,518

Cost of goods sold		29,692			12,883			52,326			27,130

Gross profit		30,285			16,501			63,586			31,388

Operating expenses
Research and development		15,530			12,101			25,770			22,273
Sales and marketing		101,598			104,535			178,333			208,114
General and administrative		766,894			893,045			1,365,807			1,517,002

Total operating expenses		884,022			1,009,681			1,569,910			1,747,389

Loss from operations		(853,737	)		(993,180	)		(1,506,324	)		(1,716,001	)

Other expenses:
Interest expense		1,924			357,446			18,355			583,830

Total other expenses		1,924			357,446			18,355			583,830

Net loss		(855,661	)		(1,350,626	)		(1,524,679	)		(2,299,831	)

Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend		(53,675	)		(27,196	)		(85,517	)		(27,196	)
Dividend declared		(45,106	)		(1,664	)		(81,183	)		(1,664	)
Net loss attributable to common shareholders	$	(954,442	)	$	(1,379,486	)	$	(1,691,379	)	$	(2,328,691	)

Net loss per common share – basic and diluted	$	(0.04	)	$	(0.06	)	$	(0.07	)	$	(0.11	)
Weighted average common shares outstanding – basic and diluted		25,470,418			21,315,242			25,287,759			21,299,171

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statement of Stockholders’ Deficiency

(Unaudited)

	Series A Preferred Stock				Series B Preferred Stock				Common Stock				Additional Paid-In		Accumulated			Total Stockholders
	Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Deficiency
Balance at December 31, 2016		1,705,154	$	1,705		-	$	-		25,046,438	$	25,046	$	20,277,882	$	(20,650,207	)	$	(345,574	)
Issuance of common stock for services		-		-		-		-		457,500		458		513,511		-			513,969
Issuance of preferred stock		-		-		1,100,000		1,100		-		-		1,098,900		-			1,100,000
Accretion of beneficial conversion feature on preferred stock		-		-		-		-		-		-		85,517		(85,517	)		-
Dividend on preferred stock		-		-		-		-		130,813		131		81,052		(81,183	)		-
Net loss		-		-		-		-		-		-		-		(1,524,679	)		(1,524,679	)
Balance at June 30, 2017		1,705,154	$	1,705		1,100,000	$	1,100		25,634,751	$	25,635	$	22,056,862	$	(22,341,586	)	$	(256,284	)

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Condensed Statements of Cash Flows

	Six Months Ended June 30,
	2017			2016
	(Unaudited)			(Unaudited)
Operating Activities
Net loss	$	(1,524,679	)	$	(2,299,831	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		31,331			18,815
Amortization of debt discount		-			293,821
Accrued interest expense included in notes payable		13,746			40,827
Fair value of warrants issued as post-maturity interest		-			246,578
Stock-based compensation		405,918			378,056
Stock-based compensation – related parties		108,051			534,098
Changes in operating assets and liabilities:
(Increase) decrease in -
Accounts receivable		11			329
Inventories		(64,305	)		(3,295	)
Deposits and prepaid expenses		22,788			17,358
Increase (decrease) in -
Accounts payable and accrued expenses		57,442			90,648
Accrued and deferred rent costs		(73,624	)		(23,839	)

Net cash used in operating activities		(1,023,321	)		(706,435	)

Investing Activities
Purchase of property and equipment		(5,500	)		(1,171	)

Net cash used in investing activities		(5,500	)		(1,171	)

Financing Activities
Proceeds from issuance of convertible notes payable		-			136,000
Proceeds from issuance of promissory notes – related party		-			140,000
Proceeds from issuance of promissory notes		100,000			170,000
Payments on promissory notes		(14,000	)		(130,000	)
Proceeds from issuance of preferred stock		1,100,000			545,000
Increase in due to related parties		77,837			110,300

Net cash provided by financing activities		1,263,837			971,300

Cash:
Net increase		235,016			263,694
Balance at beginning of period		62,520			13,850
Balance at end of period	$	297,536		$	277,544

Supplemental disclosure of cash flow information:
Cash paid for -
Interest	$	1,500		$	-
Income taxes	$	-		$	-

Non-cash financing activities:
Issuance of common stock dividends on preferred stock	$	81,183		$	1,664
Fair value of warrants issued in connection with promissory and convertible notes payable	$	-		$	245,349
Beneficial conversion feature associated with promissory and convertible notes payable	$	-		$	70,949

See accompanying notes to condensed financial statements.

Guardion Health Sciences, Inc.

Notes to Financial Statements

(Unaudited)

Six Months Ended June 30, 2017 and 2016

Organization and Business Operations

Organization and Business

Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.

The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment.

Through June 30, 2017, the Company has had limited operations, but has been primarily engaged in research, development, commercialization and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the six months ended June 30, 2017 and 2016, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z.

Going Concern and Liquidity

The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $1,524,679 and utilized cash in operating activities of $1,023,321 during the six months ended June 30, 2017, and had a stockholders’ deficit of $256,284 as of June 30, 2017. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

The Company’s independent registered public accounting firm has also included explanatory language in their report accompanying the Company’s audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Research and Development Costs

Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $25,770 and $22,273 for the six months ended June 30, 2017 and 2016, respectively.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.

The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per share valuations of the Company’s equity instruments. Management used valuations of $1.00 per share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Six Months Ended June 30,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Management considered business and market factors affecting the Company during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, management believes that $0.88 and $1.00 per share valuations are appropriate for accounting purposes for the periods ending June 30, 2017 and 2016, respectively.

The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company recognizes stock compensation expense on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock.

The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.

Net Loss per Share

The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share.

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	June 30,
	2017		2016
Warrants		2,983,666		2,873,666
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		4,308,600		908,335
		7,323,516		5,227,812

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.

In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.

The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Inventories

Inventories consisted of the following:

	June 30,		December 31,
	2017		2016
Raw materials	$	106,159	$	40,679
Finished goods		2,144		3,320
	$	108,303	$	43,999

Property and Equipment, net

Property and equipment consisted of the following:

	June 30,			December 31,
	2017			2016
Leasehold improvements	$	98,357		$	98,357
Testing equipment		145,503			145,503
Furniture and fixtures		15,348			15,348
Computer equipment		15,277			15,277
Office equipment		8,193			2,694
		282,678			277,179
Less accumulated depreciation and amortization		(194,490	)		(163,159	)
	$	88,188		$	114,020

For the six months ended June 30, 2017 and 2016, depreciation and amortization expense was $31,331 and $18,815, respectively, of which $14,650 and $12,840 was included in research and development expense, respectively, and $16,681 and $5,975 was included in general and administrative expense, respectively.

Convertible Notes Payable

	June 30,		December 31,
	2017		2016
Year of issuance:
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,811		19,323
Notes payable	$	45,811	$	44,323

In July 2010, the Company issued an unsecured convertible note payable in the amount of $25,000. The note carries simple interest at a rate of 12% per annum and became due and payable on August 1, 2013. The outstanding amounts are convertible into shares of common stock of the Company at conversion prices of $0.08 per share. This note is currently outstanding and past due, and $20,811 of accrued interest is recorded as of June 30, 2017.

Promissory Notes

	June 30,		December 31,
	2017		2016
Year of issuance:
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,314		251
Promissory notes payable, net	$	125,314	$	10,251

(a) In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $449 and $251 of accrued interest is recorded as of June 30, 2017 and December 31, 2016.

(b) In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $13,040, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $822 of additional accrued interest has been recorded.

Promissory Notes – Related Party

	June 30,		December 31,
	2017		2016
Year of issuance:
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

In 2016, the Company issued $140,000 of unsecured promissory notes to various related party investors, with interest rates ranging from 6% to 12% and a weighted average term at issuance of approximately four months. As of December 31, 2016 the remaining balance of the unpaid notes was $14,000, which was repaid during the first quarter of 2017.

Commitments and Contingencies

The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at June 30, 2017 with respect to such matters, including the matter noted below.

The Company recently received a payment demand from a former consultant to the Company alleging that he is owed approximately $192,000 for services rendered. The Company has disputed this demand and the resolution of this matter is uncertain. The Company intends to vigorously protect its rights.

On March 1, 2017, we entered into a non-binding letter of intent (“LOI”) with VectorVision, Inc., a Delaware corporation (“VectorVision”), whereby the parties set forth an outline of the terms and conditions pursuant to which we would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of our common stock. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. VectorVision’s patented standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. We believe the acquisition of VectorVision would expand our technical portfolio and further establish our position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, the completion of an audit of VectorVision’s financial statements, and other matters, no later than the August 31, 2017 expiration date of the LOI, as amended. No assurances can be provided regarding whether or when we may complete the acquisition of VectorVision. It is possible that we may never consummate this contemplated acquisition of VectorVision or we may complete such acquisition on terms materially different than those described herein.

Stockholders’ Deficit

Preferred Stock

Series A

During 2016, the Company sold 1,170,000 shares of the Company’s Series A Senior Convertible Preferred Stock (the “Series A Preferred Stock”) to various investors. The purchase price of the Series A Preferred Stock was $1.00 per share, for an aggregate purchase price of $1,170,000. In addition, during 2016, the Company issued 535,154 shares of its Series A Preferred Stock with a fair value of $784,888 upon conversion of $535,149 of notes payable and accrued interest. The Series A Preferred Stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 8% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.60 per share. Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative.

At the option of each holder, the Series A Preferred Stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more. If not converted by September 30, 2019, the preferred stock (including accrued but unpaid dividends) shall automatically and mandatorily convert into shares of common stock at $0.60 per share. Such mandatory conversion shall be subject to either a registration statement having been filed with the Securities and Exchange Commission, including the common stock underlying the Series A Preferred Stock, and being in effect, or all shares of underlying common stock being saleable under Rule 144 pursuant to the Securities Act without regard to volume limitations.

The issuance of the 1,170,000 shares of Series A Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.60 per share being less than the market price of the shares of Series A Preferred Stock at the issuance date as determined by an independent third-party valuation firm. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Preferred Stock of $779,586 at December 31, 2016, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued Series A Preferred Stock exceeded the proceeds from such issuances. The deemed dividend on the Series A Preferred Stock was accreted using the effective interest method from the respective issuance dates through the earliest conversion date of January 1, 2017. The accretion of the deemed dividend for the year ended December 31, 2016 was $760,011. The remaining balance of $19,575, representing the amount allocable to the January 1, 2017 earliest conversion date, was accreted in January 2017.

Sale of the Company’s Series A Preferred Stock was closed on December 31, 2016.

During the six months ended June 30, 2017 the Company declared dividends of $67,646 on its Series A Preferred Stock which were satisfied in full through the issuance of an aggregate of 112,759 shares of common stock.

Series B

As of June 30, 2017, the Company had sold 1,100,000 shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”) to various investors. The purchase price of the Series B Preferred Stock was $1.00 per share, for an aggregate purchase price of $1,100,000. The Series B Preferred Stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 6% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.75 per share. Series B Preferred Stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holders thereof into common stock at a conversion rate of $0.75 per share. The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B Preferred Stock is senior to all common stock and junior to the Series A Preferred Stock in terms of liquidation preferences.

The issuance of the Series B Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, warrants were issued to purchasers of the Series B Preferred Stock who had previously participated in the 2016 Series A Preferred Stock offering. The Company accounted for the beneficial conversion feature, including an allocation of proceeds for the warrants on a relative fair value basis, in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series B Preferred Stock of $234,840 at June 30, 2017, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the Series B Preferred Stock exceeded the proceeds from such issuances. The deemed dividend on the Series B Preferred Stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of December 31, 2017. The accretion of the deemed dividend for the six months ended June 30, 2017 was $65,942.

During the six months ended June 30, 2017, the Company declared dividends of $13,537 on its Series B Preferred Stock which were satisfied in full through the issuance of an aggregate of 18,054 shares of common stock.

Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock, first to holders of Series A Preferred Stock, then to holders of Series B Preferred Stock, in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full.

Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $500,000 of preferred stock was sold of that series, and at least $250,000 of the related class of preferred stock is still outstanding. This demand registration right and the piggyback registration rights will terminate when all shares of preferred stock have been converted into common stock.

In the event of a merger or acquisition or change in control of the Company, both classes of preferred stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction.

Common Stock

During 2016 and 2015, the Company issued 3,459,091 shares of common stock for services rendered. The aggregate grant date fair value of the stock was $3,803,980. 1,405,000 of these shares were restricted shares subject to vesting requirements over 9 to 12 months and subject to forfeiture if vesting conditions were not met. As of December 31, 2016, 1,052,500 of the restricted shares with a fair value of $1,580,372 had vested, and 352,500 restricted shares with a fair value of $111,369 remained to be vested. As of June 30, 2017, all 1,405,000 shares have fully vested.

Additional details of the Company’s restricted common stock are as follows:

	Number of Shares			Weighted Average Grant Date Fair Value Per Share
Non-vested, December 31, 2016		352,500			1.13
Issued		162,500			0.88
Vested		(515,000	)		1.05
Forfeited		-			-
Non-vested, June 30, 2017		-		$	-

Warrants

During March 2017, in connection with the Series B Preferred Stock offering discussed above, the Company issued a total of 60,000 warrants as additional incentive to investors who had previously invested in the Company’s Series A Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $0.75 per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $51,796, based upon the Black-Scholes option-pricing model, with a stock price of $0.88, volatility of 135%, and an average risk-free interest rate of 1.61%.

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
June 30, 2017, all exercisable		2,983,666

As of June 30, 2017, the Company had an aggregate of 2,983,666 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $0.37, weighted average remaining life of 1.4 years and aggregate intrinsic value of $1,293,512, based upon a stock valuation of $0.88 per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants.

10.

Related Party Transactions

Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of June 30, 2017 and December 31, 2016, the Company had $169,320 and $91,483, respectively, due to related parties.

During the six months ended June 30, 2017, the Company incurred $125,000 of salary expense and paid $50,000 in salary to our CEO, Michael Favish. During the twelve-month period ended December 31, 2016, the Company incurred salary expense of $250,000 and paid $48,500 in salary to Mr. Favish. Accrued amounts are included in general and administrative expenses.

11.

Subsequent Events

During July 2017, the Company issued 6,800 shares of fully vested common stock to consultants for services rendered.

During July 2017, the Company issued 1,975,000 additional shares of Series B Preferred Stock to investors for an aggregate purchase price of $1,975,000. The Series B Preferred Stock issued in July 2017 has the same terms as the Series B Preferred Stock issued prior to July 2017. Sales of the Series B Preferred Stock was closed on July 31, 2017.

During July 2017, the Company repaid a $100,000 unsecured promissory note from a related party investor.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Presentation of Information

As used in this Quarterly Report on Form 10-Q, the terms “we,” “us” “our” and the “Company” mean Guardion Health Sciences, Inc. unless the context requires otherwise. The following discussion and analysis should be read in conjunction with our financial statements and the related notes that appear elsewhere in this report and our audited financing statements for the year ended December 31, 2016, and the notes thereto, which are set forth in the 2016 Form 10-K.. All dollar amounts refer to U.S. dollars unless otherwise indicated.

Overview

Guardion Health Sciences, Inc. was formed in December 2009 in California as a limited liability company under the name P4L Health Sciences, LLC and we subsequently changed our name to Guardion Health Sciences, LLC. On June 30, 2015, we converted from a California limited liability company to a Delaware corporation, changing our name to Guardion Health Sciences, Inc.

We are a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment. A depleted macular protective pigment is a modifiable risk factor for retina based diseases such as age-related macular degeneration (“AMD”), computer vision syndrome (“CVS”) and diabetic retinopathy. Additional research has also shown a depleted macular protective pigment to be a biomarker for neurodegenerative diseases such as Alzheimer’s and dementia. We have had limited operations to date, and have primarily been engaged in research, development, commercialization and capital raising.

We have also developed a proprietary medical device called the MapcatSF^®that accurately measures the macular pigment optical density (“MPOD”). We invented our own proprietary patented technology embodied in the MapcatSF. On November 8, 2016, the USPTO issued patent number 9,486,136 for the MapcatSF invention. Using the MapcatSF to measure the MPOD allows one to monitor the increase in the density of the macular protective pigment after taking Lumega-Z. The MapcatSF is a non-mydriatic, non-invasive device that is designed to accurately measure the MPOD, the lens optical density and lens equivalent age, thereby creating an evidence-based protocol that is shared with the patient. A non-mydriatic device is one that does not require dilation of the pupil for it to function. The MapcatSF is intended to be the first device using a patented “single fixation” process and “automatic lens density correction” that produces accurate serialized data.

Lumega-Z has a patent-pending formula that replenishes and restores the macular protective pigment simultaneously delivering critical and essential nutrients to the eye. Formulated by Dr. Sheldon Hendler in 2010, modifications were made over a two-year period to improve the taste and method of delivery. We believe that there is an increasing level of acceptance of medical foods as a primary therapy by patients and healthcare providers to treat pain syndromes, sleep and cognitive disorders, obesity, hypertension, and viral infection. In clinical practice, medical foods are being prescribed as both a standalone therapy and as an adjunct therapy to low doses of commonly prescribed drugs. We believe that medical foods will continue to grow in importance over the coming years.

By combining our MapcatSF medical device and Lumega-Z medical food, we have developed, based on our management’s knowledge of the industry, what we believe to be the only reliable two-pronged, evidence-based protocol for replenishing and restoring the macular protective pigment and increasing overall retinal health.

Recent Developments

Going Concern

Our financial statements have been prepared assuming we will continue as a going concern. We have utilized cash in operating activities of $1,023,321 and $706,435 during the six months ended June 30, 2017 and 2016, respectively, and had a total stockholders’ deficiency of $256,284 and $345,574 as of June 30, 2017 and December 31, 2016, respectively. We expect to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued.

Our independent registered public accounting firm have also included explanatory language in their report accompanying our audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K that there is substantial doubt about our ability to continue as a going concern. Our financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of us to continue as a going concern.

We will continue to incur significant expenses for commercialization activities related to our lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build our infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, our long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. We are continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that we will be able to secure such additional financing in the amounts necessary to fully fund our operating requirements on acceptable terms or at all. If we are unable to access sufficient capital resources on a timely basis, we may be forced to reduce or discontinue our technology and product development programs and curtail or cease operations.

Recent Accounting Pronouncements

See Note 2 to the condensed financial statements for our management’s discussion of recent accounting pronouncements.

Critical Accounting Policies and Estimates

Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Our financial statements included herein include all adjustments, consisting of only normal recurring adjustments, necessary to present fairly our financial position, results of operations and cash flows.

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements.

Stock-Based Compensation

We periodically issue stock-based compensation to officers, directors, and other consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers and directors, and to employees in the future which will include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until we have established a trading market for our common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; we have never declared or paid dividends on our common stock and have no plans to do so for the foreseeable future.

The fair value of our common stock was determined based on our management’s judgment. In order to assist management in calculating such fair value, we retained an independent third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per share valuations of our equity used at June 30, 2017 and December 31, 2016. Management used valuations of $1.00 per share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016, based on various inputs, including valuation reports prepared by the third-party valuation firm as of December 31, 2016 and 2015. The fully diluted per share equivalent price is lower in 2017 than in early 2016 due to the dilutive effect of the issuance of common shares as compensation during the period. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. We considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Six Months Ended June 30,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Our management considered business and market factors affecting us during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, our management believes that $0.88 and $1.00 per share valuations are appropriate for accounting purposes during the periods presented.

We account for stock and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

We recognize stock compensation expense on stock issued to consultants and other service providers for the excess of fair value of the stock over the price paid for the stock.

We recognize the fair value of stock-based compensation within our statements of operations with classification depending on the nature of the services rendered. We issue new shares to satisfy warrant exercises.

During the six months ended June 30, 2017 and 2016, we recognized aggregate stock-compensation expense of $513,969 and $912,154, respectively, based upon deemed stock values ranging from $0.88 to $1.14 per share, of which $492,983 and $812,409 was recorded in general and administrative expense, $20,357 and $96,356 was recorded in sales and marketing expense, and $629 and $3,389 was recorded in research and development expense, respectively.

Plan of Operations

General Overview

Based on the availability of sufficient funding, we intend to increase our commercialization activities and:

further the commercial production of the MapcatSF, starting with the manufacture of at least ten new units for sale or lease to our customers and for use in our internal clinics;

expand our domestic sales and marketing efforts, which include revamping our web site and new promotional materials;

increase production of Lumega-Z as is necessary to support the additional sales resulting from the deployment of additional MapcatSF units and increased marketing and promotional activity;

commence certain FDA electrical safety testing of the MapcatSF; and

increase our focus on intellectual property protection and strategy.

The FDA and other regulatory bodies require electronic medical devices to comply with IEC 60601 standards. The International Electrical Commission (“IEC”) established technical standards for the safety and effectiveness of medical electrical equipment. Adherence to these standards is required for commercialization of electrical medical equipment. As a medical device powered by electricity, the MapcatSF will need to undergo testing to demonstrate compliance with the IEC 60601 standards. This testing is typically conducted by a Nationally Recognized Testing Laboratory (“NRTL”), which is an independent laboratory recognized by the Occupational Safety and Health Administration (“OSHA”) to test products to the specifications of applicable product safety standards. We are in discussions with our contract manufacturer of the MapcatSF to engage an NRTL at the appropriate juncture prior to commercialization of the MapcatSF. The relevant predicate device for the MapcatSF is the MPS II, the applicable Class I product code for the MapcatSF is HJW and the applicable Code of Federal Regulation is 886.1050. The FDA does not require test documents to be submitted to the FDA for a Class I medical device, but that the evidence of such testing be placed in a Design History file and be kept internally at the company or manufacturer and readily available should the FDA or other regulatory bodies request to review the testing documents. While the FDA does not require that a Class I medical device have formal validation, we expect to complete applicable IEC 60601-1 testing prior to commercialization as we believe in marketing a product that has evidence that it is safe and effective.

Results of Operations

Through June 30, 2017, we had limited operations and have primarily been engaged in research, development, commercialization and capital raising. We have incurred significant expenditures for the development of our products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. We had limited revenue during the six-month periods ended June 30, 2017 and 2016, all of which was generated by the sale of our proprietary product, Lumega-Z.

Comparison of Three Months Ended June 30, 2017 and 2016

	Three Months Ended June 31,
	2017			2016			Change
Revenue	$	59,977		$	29,384		$	30,593		104	%
Cost of goods sold		29,692			12,883			16,809		130	%
Gross Profit		30,285			16,501			13,784		84	%
Operating Expenses:
Research and development		15,530			12,101			3,429		28	%
Sales and marketing		101,598			104,535			(2,937	)	(3	)%
General and administrative		766,894			893,045			(126,151	)	(14	)%
Total Operating Expenses		884,022			1,009,681			(125,659	)	(12	)%
Loss from Operations		(853,737	)		(993,180	)		139,443		(14	)%
Other Expense:
Interest expense		1,924			357,446			(355,522	)	(99	)%
Net Loss	$	(855,661	)	$	(1,350,626	)	$	494,965		(37	)%

Revenue

For the three months ended June 30, 2017, revenue from the sale of Lumega-Z was $59,977 compared to $29,384 for the three months ended June 30, 2016, resulting in an increase of $30,593 or 104%. The increase is reflective of an increased customer base as we expand into new clinics.

Cost of Goods Sold

For the three months ended June 30, 2017, cost of goods sold from the sale of Lumega-Z was $29,692 compared to $12,883 for the three months ended June 30, 2016, resulting in an increase of $16,809 or 130%. The increase corresponds to the additional sales recorded in 2017.

Research and Development

For the three months ended June 30, 2017, research and development costs were $15,530 compared to $12,101 for the three months ended June 30, 2016, resulting an increase of $3,429 or 28%. The increase resulted from a modest increase in legal costs associated with our intellectual property.

Sales and Marketing

For the three months ended June 30, 2017, sales and marketing expenses were $101,598 compared to $104,535 for the three months ended June 30, 2016. The decrease in sales and marketing expenses of $2,937 or 3% compared to the prior period was due primarily to a decrease in non-cash stock compensation expense of approximately $38,000, partially offset by increases in consulting costs.

General and Administrative

For the three months ended June 30, 2017, general and administrative expenses were $766,894 compared to $893,045 for the three months ended June 30, 2016. The decrease of $126,151 or 14% compared to the prior period was primarily due to a $319,000 reduction in non-cash stock compensation expense from the prior period, partially offset by increases in accrued legal, professional and management fees.

Interest Expense

For the three months ended June 30, 2017, interest expense was $1,924 compared to $357,446 for the three months ended June 30, 2016. The decrease in interest expense of $355,522 or 99% compared to the prior period was due to the repayment or conversion, since June 30, 2016, of the majority of the promissory notes and convertible debt that had been outstanding during the three months ended June 30, 2016. Included in the $1,924 amount is $1,570 that relates to notes that are past due as of June 30, 2017.

Net Loss

For the three months ended June 30, 2017, we incurred a net loss of $855,661, compared to a net loss of $1,350,626 for the three months ended June 30, 2016. The decrease in net loss of $494,965 or 37% compared to the prior year period was primarily due to the reduction of $355,522 in interest expense related to promissory notes and convertible debt that was repaid or converted since June 30, 2016, as well as to reduced stock compensation expense in 2017 ($353,875 was recognized in the second quarter of 2017 versus $661,441 in the prior year period).

Comparison of Six Months Ended June 30, 2017 and 2016

	Six Months Ended June 31,
	2017			2016			Change
Revenue	$	115,912		$	58,518		$	57,394		98	%
Cost of goods sold		52,326			27,130			25,196		93	%
Gross Profit		63,586			31,388			32,198		103	%
Operating Expenses:
Research and development		25,770			22,273			3,497		16	%
Sales and marketing		178,333			208,114			(29,781	)	(14	)%
General and administrative		1,365,807			1,517,002			(151,195	)	(10	)%
Total Operating Expenses		1,569,910			1,747,389			(177,479	)	(10	)%
Loss from Operations		(1,506,324	)		(1,716,001	)		209,677		(12	)%
Other Expense:
Interest expense		18,355			583,830			(565,475	)	(97	)%
Net Loss	$	(1,524,679	)	$	(2,299,831	)	$	775,152		(34	)%

Revenue

For the six months ended June 30, 2017, revenue from the sale of Lumega-Z was $115,912 compared to $58,518 for the six months ended June 30, 2016, resulting in an increase of $57,394 or 98%. The increase is reflective of an increased customer base as we expand into new clinics.

Cost of Goods Sold

For the six months ended June 30, 2017, cost of goods sold from the sale of Lumega-Z was $52,326 compared to $27,130 for the six months ended June 30, 2016, resulting in an increase of $25,196 or 93%. The increase corresponds to the additional sales recorded in 2017.

Research and Development

For the six months ended June 30, 2017, research and development costs were $25,770 compared to $22,273 for the six months ended June 30, 2016, resulting in an increase of $3,497 or 16%. The increase resulted from a modest increase in legal costs associated with our intellectual property.

Sales and Marketing

For the six months ended June 30, 2017, sales and marketing expenses were $178,333 compared to $208,114 for the six months ended June 30, 2016. The decrease in sales and marketing expenses of $29,781 or 14% compared to the prior period was due primarily to a decrease in non-cash stock compensation expense of approximately $76,000, partially offset by increases in consulting, marketing and promotional costs.

General and Administrative

For the six months ended June 30, 2017, general and administrative expenses were $1,365,807 compared to $1,517,002 for the six months ended June 30, 2016. The decrease of $151,195 or 10% compared to the prior period was primarily due to a $319,000 reduction in non-cash stock compensation expense from the prior period, partially offset by increases in accrued legal, professional and management fees.

Interest Expense

For the six months ended June 30, 2017, interest expense was $18,355 compared to $583,830 for the comparable period of 2016. The decrease in interest expense of $565,475 or 97% compared to the prior year was due to the repayment or conversion, since June 30 2016, of the majority of promissory notes and convertible debt that had been outstanding during the six months ended June 30, 2016. Included in the $18,355 amount is $2,310 that relates to notes that are past due as of June 30, 2017.

Net Loss

For the six months ended June 30, 2017, we incurred a net loss of $1,524,679, compared to a net loss of $2,299,831 for the six months ended June 30, 2016. The decrease in net loss of $775,152 or 34% compared to the prior year period was primarily due to the reduction of $565,475 in interest expense related to promissory notes and convertible debt that were repaid or converted since June 30, 2016, as well as to reduced stock compensation expense in 2017 ($513,969 was recognized in the first six months of 2017 versus $912,154 in the prior year period).

Liquidity and Capital Resources

Since our formation in 2009, we have devoted substantial effort and capital resources to the development and commercialization activities related to our lead product Lumega-Z and our MapcatSF medical device. As a result of these activities we utilized cash in operating activities of $1,023,321 during the six months ended June 30, 2017. We had negative working capital of $354,942 at June 30, 2017. As of June 30, 2017, we had cash in the amount of $297,536 and no available borrowings. Our financing has historically come from the issuance of convertible notes, promissory notes and from the sale of common and preferred stock and exercise of warrants. Some of our notes have remained outstanding beyond their stated maturity dates, resulting in additional interest charges due upon settlement.

Our financial statements have been prepared assuming we will continue as a going concern. We expect to continue to incur net losses and negative operating cash flows in the near-term. As a result, our management has concluded that there is substantial doubt about our ability to continue as a going concern within one year of the date that the financial statements are issued.

Our independent registered public accounting firm has also included explanatory language in their report accompanying our audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K that there is substantial doubt about the Company’s ability to continue as a going concern. Our financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

We will continue to incur significant expenses for commercialization activities related to our lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build our infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, our long-term viability and growth will depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. We are continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that we will be able to secure such additional financing in the amounts necessary to fully fund our operating requirements on acceptable terms or at all. If we are unable to access sufficient capital resources on a timely basis, we may be forced to reduce or discontinue its technology and product development programs and ultimately curtail or cease operations.

Sources and Uses of Cash

The following table sets forth our major sources and uses of cash for each of the following periods:

	Six Months Ended June 30,
	2017			2016
Net cash used in operating activities	$	(1,023,321	)	$	(706,435	)
Net cash used in investing activities		(5,500	)		(1,171	)
Net cash provided by financing activities		1,263,837			971,300
Net increase (decrease) in cash	$	235,016		$	263,694

Operating Activities

Net cash used in operating activities was $1,023,321 during the six months ended June 30, 2017, versus $706,435 used during the comparable prior year period. The increase in 2017 was due primarily to higher sales, marketing, and travel costs, in addition to paydown of our accrued rent liability and the buildup of inventory stock.

Investing Activities

Net cash used in investing activities was $5,500 for the six months ended June 30, 2017 and $1,171 for the six months ended June 30, 2016, and consisted of investment in office and computer equipment.

Financing Activities

Net cash provided by financing activities was $1,263,837 for the six months ended June 30, 2017. Financing activities for the period provided proceeds of $100,000 from the issuance of short-term loans partially offset by payments on those loans of $14,000, $1,100,000 in proceeds from the issuance of Series B Preferred Stock, and $77,837 in amounts due to related parties on a net basis.

Net cash provided by financing activities was $971,300 the six months ended June 30, 2016. Financing activities for the period provided proceeds of $446,000 from the issuance of convertible notes and promissory notes partially offset by payments on those loans of $130,000, $545,000 in proceeds from the issuance of Series A Preferred Stock, and $110,300 in amounts due to related parties on a net basis.

Off-Balance Sheet Arrangements

At June 30, 2017 and December 31, 2016, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon this evaluation, the Chief Executive Officer and Chief Accounting Officer each concluded that the Company’s disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that such information has been accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, in a manner that allows timely decisions regarding required disclosure. There have been no changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the second quarter ended in 2017 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 1A. RISK FACTORS

As of the date of this filing, there have been no material changes to the Risk Factors included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016, as filed with the SEC on March 30, 2017 (the “2016 Form 10-K”). The Risk Factors set forth in the 2016 Form 10-K and in the other documents the Company files with the SEC from time to time should be read carefully in connection with evaluating the Company’s business and in connection with the forward-looking statements contained in this Quarterly Report on Form 10-Q. Any of the risks described in the 2016 Form 10-K or in the other documents the Company files with the SEC from time to time could materially adversely affect the Company’s business, financial condition or future results and the actual outcome of matters as to which forward-looking statements are made. These are not the only risks that the Company faces. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company’s business, financial condition and/or operating results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the six months ended June 30, 2017, the Company sold 1,100,000 shares of the Company’s Series B Convertible Preferred Stock to various investors. The purchase price of the stock was $1.00 per share, for an aggregate purchase price of $1,100,000. The stock has a stated value of $1.00 per share and accrues an annual dividend at the rate of 6% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $0.75 per share. Series B preferred stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holder into common stock at $0.75 per share. The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B preferred stock is senior to all Common Stock and junior to the Series A preferred stock.

During March 2017, in connection with the Series B Convertible Preferred Stock offering, the Company issued a total of 60,000 warrants as additional incentive to investors who had previously invested in the Company’s Series A Senior Convertible Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $0.75 per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $51,796, based upon the Black-Scholes option-pricing model, with a stock price of $0.88, volatility of 135%, and an average risk-free interest rate of 1.61%.

The offerings of Series B Preferred Stock were exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D and/or Regulation S promulgated thereunder. No sales commissions were paid in connection with these transactions and no placement agent or underwriter was involved.

During the first six months of 2017, the Company issued 457,500 shares of common stock to service providers. The aggregate fair value of the stock was $402,600 based on a valuation per share of $0.88 on the date of grant. 162,500 of these shares were restricted shares subject to vesting requirements over 4 months and subject to forfeiture if vesting conditions were not met. As of June 30, 2017, all such shares have fully vested. The securities issued in these transactions were exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, as such transaction did not involve any public offering. No sales commissions were paid in connection with the transactions and no placement agent or underwriter was involved.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 10th day of August, 2017.

Signature	Title	Date

/s/ Michael Favish	CEO, President and	August 10, 2017
Michael Favish	Chairman of the Board (Principal Executive Officer)

/s/ John Townsend	Controller and Chief Accounting Officer	August 10, 2017
John Townsend	(Principal Accounting Officer)

INDEX TO EXHIBITS

Exhibit No.			Description
3.1			Articles of Organization of P4L Health Sciences, LLC and restatement changing name to Guardion Health Sciences, LLC filed in California (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 11, 2016)
3.2			Articles of Conversion; Delaware and California (incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 11, 2016)
3.3			The Company’s Certificate of Incorporation and amendment thereto (incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 11, 2016
3.4			Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form S-1 filed with the SEC on February 11, 2016)
3.5			Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of Series A Convertible Preferred Stock with Certificate of Correction (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 5, 2017)
3.6			Certificate of Designation of the Rights, Preferences, Privileges and Restrictions of Series B Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 23, 2017)
4.1			Form of Preferred Stock Purchase Agreement (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 5, 2017)
4.2			Form of Series B Preferred Stock Purchase Agreement (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 23, 2017)
31.1			Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2			Certification of Chief Accounting Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*			Certification of Chief Executive Officer and Chief Accounting Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101			The following materials from the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2017, formatted in XBRL (eXtensible Business Reporting Language), (i) Balance Sheets, (ii) Statements of Income, (iii) Statements of Comprehensive Income, (iv) Statements of Cash Flows, (v) Statement of Stockholders’ Equity and (vi) Notes to Financial Statements

A certification furnished pursuant to Item 601(b)(2) of the Regulation S-K will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

EX-31.1 2 v472618_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION

I, Michael Favish, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2017

/s/ Michael Favish

Michael Favish

Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 v472618_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION

I, John Townsend, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2017	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-32.1 4 v472618_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ENACTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Guardion Health Sciences, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Michael Favish, Chief Executive Officer of the Company, and John Townsend, Controller and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

August 10, 2017	/s/ Michael Favish
	Michael Favish
	Chief Executive Officer
	(Principal Executive Officer)


August 10, 2017	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-101.INS 5 cik0001642375-20170630.xml XBRL INSTANCE DOCUMENT 0001642375 2016-01-01 2016-06-30 0001642375 2016-01-01 2016-12-31 0001642375 2017-01-01 2017-06-30 0001642375 2017-01-31 0001642375 2017-03-31 0001642375 2016-04-01 2016-06-30 0001642375 2017-04-01 2017-06-30 0001642375 2016-06-30 0001642375 2017-06-30 0001642375 2017-07-01 2017-07-31 0001642375 2017-08-10 0001642375 2016-09-30 0001642375 2016-12-31 0001642375 2015-12-31 0001642375 us-gaap:SeriesAPreferredStockMember 2017-06-30 0001642375 us-gaap:SeriesBPreferredStockMember 2017-06-30 0001642375 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001642375 us-gaap:SeriesBPreferredStockMember 2016-12-31 0001642375 us-gaap:CommonStockMember 2016-12-31 0001642375 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001642375 us-gaap:RetainedEarningsMember 2016-12-31 0001642375 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-06-30 0001642375 us-gaap:RetainedEarningsMember 2017-01-01 2017-06-30 0001642375 us-gaap:CommonStockMember 2017-06-30 0001642375 us-gaap:AdditionalPaidInCapitalMember 2017-06-30 0001642375 us-gaap:RetainedEarningsMember 2017-06-30 0001642375 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-06-30 0001642375 us-gaap:WarrantMember 2016-01-01 2016-06-30 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2016-01-01 2016-06-30 0001642375 cik0001642375:ConversionOfPreferredStockMember 2017-01-01 2017-06-30 0001642375 cik0001642375:ConversionOfPreferredStockMember 2016-01-01 2016-06-30 0001642375 us-gaap:OfficeEquipmentMember 2017-06-30 0001642375 us-gaap:OfficeEquipmentMember 2016-12-31 0001642375 us-gaap:ComputerEquipmentMember 2017-06-30 0001642375 us-gaap:ComputerEquipmentMember 2016-12-31 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2017-06-30 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2016-12-31 0001642375 us-gaap:LeaseholdImprovementsMember 2017-06-30 0001642375 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001642375 us-gaap:FurnitureAndFixturesMember 2017-06-30 0001642375 us-gaap:FurnitureAndFixturesMember 2016-12-31 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2017-01-01 2017-06-30 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2016-01-01 2016-06-30 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:DueAugust2013Member cik0001642375:UnsecuredNotesPayableMember 2017-06-30 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:DueAugust2013Member cik0001642375:UnsecuredNotesPayableMember 2016-12-31 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:UnsecuredNotesPayableMember 2017-06-30 0001642375 us-gaap:ConvertibleNotesPayableMember cik0001642375:UnsecuredNotesPayableMember 2016-12-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2010-07-01 2010-07-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2010-07-31 0001642375 us-gaap:ConvertibleNotesPayableMember us-gaap:UnsecuredDebtMember 2017-06-30 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:UnsecuredDebtMember 2017-06-30 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:UnsecuredDebtMember 2016-12-31 0001642375 cik0001642375:DueNovember2016Member us-gaap:NotesPayableOtherPayablesMember 2017-06-30 0001642375 cik0001642375:DueNovember2016Member us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001642375 cik0001642375:DueMay2017Member us-gaap:NotesPayableOtherPayablesMember 2017-06-30 0001642375 cik0001642375:DueMay2017Member us-gaap:NotesPayableOtherPayablesMember 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-01-01 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:MinimumMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 us-gaap:NotesPayableOtherPayablesMember us-gaap:MaximumMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 cik0001642375:TwoThousandSixteenIssuancesMember 2016-12-31 0001642375 cik0001642375:PromissoryNoteMember us-gaap:InvestorMember 2017-01-31 0001642375 cik0001642375:PromissoryNoteMember us-gaap:InvestorMember 2017-01-01 2017-01-31 0001642375 us-gaap:InvestorMember cik0001642375:DueSeptember2016Member us-gaap:UnsecuredDebtMember 2017-06-30 0001642375 us-gaap:InvestorMember cik0001642375:DueSeptember2016Member us-gaap:UnsecuredDebtMember 2016-12-31 0001642375 us-gaap:InvestorMember 2017-06-30 0001642375 us-gaap:InvestorMember 2016-12-31 0001642375 us-gaap:InvestorMember cik0001642375:TwoThousandSixteenIssuancesMember 2016-01-01 2016-12-31 0001642375 us-gaap:UnsecuredDebtMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001642375 us-gaap:UnsecuredDebtMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001642375 us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:PreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:DividendDeclaredMember us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:MinimumMember us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:MinimumMember 2017-06-30 0001642375 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:CommonStockMember us-gaap:MinimumMember 2016-01-01 2016-12-31 0001642375 us-gaap:CommonStockMember us-gaap:MaximumMember 2016-01-01 2016-12-31 0001642375 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0001642375 us-gaap:RestrictedStockMember 2016-12-31 0001642375 us-gaap:RestrictedStockMember 2017-06-30 0001642375 us-gaap:WarrantMember 2017-06-30 0001642375 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001642375 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-06-30 0001642375 us-gaap:ChiefExecutiveOfficerMember 2017-01-01 2017-06-30 0001642375 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001642375 us-gaap:ChiefExecutiveOfficerMember 2016-01-01 2016-12-31 0001642375 us-gaap:ConvertibleNotesPayableMember 2017-01-01 2017-06-30 0001642375 us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-06-30 0001642375 us-gaap:SubsequentEventMember 2017-07-01 2017-07-31 0001642375 us-gaap:NotesPayableOtherPayablesMember 2017-01-01 2017-06-30 0001642375 us-gaap:SubsequentEventMember us-gaap:SeriesBPreferredStockMember 2017-07-01 2017-07-31 0001642375 us-gaap:InvestorMember 2017-01-01 2017-06-30 0001642375 cik0001642375:TwoThousandSixteenIssuancesMember 2017-06-30 0001642375 us-gaap:InvestorMember 2017-01-01 2017-06-30 0001642375 cik0001642375:PromissoryNoteMember us-gaap:InvestorMember 2017-06-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure

297536

62520

1662

1673

108303

43999

6576

29363

414077

137555

10470

88188

114020

512735

262045

413907

356467

14667

88290

169320

91483

45811

44323

769019

607619

25635

25046

22056862

20277882

-22341586

-20650207

512735

262045

-256284 -345574

125314

10251

16805

1705

1100

1705

115912

58518

52326

27130

63586

31388

25770

22273

178333

208114

1365807

1517002

1569910

1747389

-1506324

-1716001

18355

583830

18355

583830

-1524679

-2299831

-0.07

-0.11

25287759

21299171

85517 27196

81183

1664

-1691379

-2328691

59977

29384

29692

12883

30285

16501

15530

12101

101598

104535

766894

893045

884022

1009681

-853737

-993180

1924

357446

1924

357446

-855661

-1350626

-0.04

-0.06

25470418

21315242

53675 27196

45106

1664

-954442

-1379486

-345574

25046

20277882

-20650207

25046438

513969 458 513511 0 457500 1100000 0 1098900 0 0 0 0 85517 -85517 0 131 81052 -81183 130813

-1524679

-256284

25635

22056862

-22341586

25634751

1705

1705154

1705

1100

1705154

1100000

0 0 0 0 0 1100 0 1100000 0 0 0

31331

18815

293821

13746

40827

-11

-329

64305

3295

-22788

-17358

57442

90648

-73624

-23839

-1023321

-706435

5500

1171

-5500

-1171

136000

1263837

971300

235016

263694

13850

277544

246578

405918

378056

108051 534098

100000

170000

14000

130000

0 245349 0 70949

1500

140000

1100000

545000

77837

110300

256284

1.00

0.16 0.16

0.0248

0.0227

0.16

0.05 0.05 0.65 0.63 0 0

0.88

1.00

2983666

31250

2873666

1445811

4308600

908335

106159

40679

2144

3320

8193

2694

15277

145503

98357

15348

194490

163159

31331

18815

14650

12840

16681

5975

25000

20811

19323

45811

44323

25000

0.12

0.08

20811

15314

251

125314

10251

10000

100000

170000

0.04

0.09

10000

0.75

13040

100000

P120D

0.06

8000

14000

2805

16805

140000

0.06

0.12

535149

1.00

1170000

1.00

1170000

535154

784888

0.08

0.60

779586 760011 19575

0.60

67646

65942 234840

18054

13537

500000

250000

3459091

P9M

P12M

162500

515000

1.05

0.88

352500

1.13

60000 0 0

2923666

2983666

1293512

0.37

P1Y4M24D

169320

91483

125000

50000

250000

48500

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="center"></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 1.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Organization and Business Operations</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Organization and Business</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z<sup style="font-style:normal">®</sup> that replenishes and restores the macular protective pigment.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Through June 30, 2017, the Company has had limited operations, but has been primarily engaged in research, development, commercialization and capital raising. The Company has incurred significant expenditures for the development of the Company's products and intellectual property, which includes research and development of both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the six months ended June 30, 2017 and 2016, all of which was generated by the sale of the Company’s proprietary product, Lumega-Z.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Going Concern and Liquidity</font></i></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,524,679</font> and utilized cash in operating activities of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,023,321</font> during the six months ended June 30, 2017, and had a stockholders’ deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">256,284</font> as of June 30, 2017. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s independent registered public accounting firm has also included explanatory language in their report accompanying the Company’s audited financial statements for the year ended December 31, 2016 included in the 2016 Form 10-K that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.</div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 2.</font></strong></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Summary of Significant Accounting Policies</font></strong></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Basis of Presentation and Use of Estimates</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Research and Development Costs</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,770</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22,273</font> for the six months ended June 30, 2017 and 2016, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <strong> <i>Stock-Based Compensation</i></strong></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per share valuations of the Company’s equity instruments. Management used valuations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Management considered business and market factors affecting the Company during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, management believes that $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share valuations are appropriate for accounting purposes for the periods ending June 30, 2017 and 2016, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes stock compensation expense on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Net Loss per Share</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share.</div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,873,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Estimated shares issuable upon conversion of convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">31,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,445,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Shares issuable upon conversion of convertible preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,308,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">908,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,323,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,227,812</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  <strong><i>Stock-Based Compensation</i></strong></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Stock-based payments to officers and directors, and to employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm whose input was utilized in determining the related per share valuations of the Company’s equity instruments. Management used valuations of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share in its fair value calculations for the periods between January 1, 2016 and September 30, 2016, and $0.88 per share for periods after September 30, 2016. The current valuation of $0.88 per share is lower than previous valuations due to the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Management considered business and market factors affecting the Company during the six-month periods ended June 30, 2017 and 2016, including capital raising efforts, proprietary technology, and other factors. Based on this evaluation, management believes that $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share valuations are appropriate for accounting purposes for the periods ending June 30, 2017 and 2016, respectively.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB where the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes stock compensation expense on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 90%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="24%" colspan="6"> <div style="CLEAR:both;CLEAR: both"> Six Months Ended June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Discount rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Risk free rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.48</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2.27</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Rate of return</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">16</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Sustainable growth rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Company survival probability</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">65</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">63</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="64%"> <div style="CLEAR:both;CLEAR: both">Liquidation value</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:center; TEXT-INDENT: 0in; WIDTH: 100%" align="center"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0px:auto; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="center"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Warrants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">2,873,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Estimated shares issuable upon conversion of convertible notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">31,250</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1,445,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Shares issuable upon conversion of convertible preferred stock</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">4,308,600</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">908,335</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">7,323,516</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">5,227,812</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

5227812

7323516

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="LINE-HEIGHT: 107%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.5in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="48"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt"> <b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> 11.</font></b></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Subsequent Events</font></b></div> </td> </tr> </table> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During July 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,800</font> shares of fully vested common stock to consultants for services rendered.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">During July 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,975,000</font> additional shares of Series B Preferred Stock to investors for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,975,000</font>. The Series B Preferred Stock issued in July 2017 has the same terms as the Series B Preferred Stock issued prior to July 2017. Sales of the Series B Preferred Stock was closed on July 31, 2017.</div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During July 2017, the Company repaid a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> unsecured promissory note from a related party investor.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt"><strong>3.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><strong> Inventories</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Inventories consisted of the following:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>106,159</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>40,679</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,144</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,320</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>108,303</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>43,999</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt"><strong>4.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><strong>Property and Equipment, net</strong></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Property and equipment consisted of the following: </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Testing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,193</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>282,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>277,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(194,490)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(163,159)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>88,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>114,020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">For the six months ended June 30, 2017 and 2016, depreciation and amortization expense was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,331</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">18,815</font>, respectively, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14,650</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,840</font> was included in research and development expense, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,681</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5,975</font> was included in general and administrative expense, respectively.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Property and equipment consisted of the following: </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Leasehold improvements</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>98,357</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Testing equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>145,503</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Furniture and fixtures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,348</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Computer equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>15,277</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Office equipment</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,193</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,694</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>282,678</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>277,179</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Less accumulated depreciation and amortization</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(194,490)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>(163,159)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>88,188</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>114,020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

282678

277179

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt"><strong>5.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><strong>Convertible Notes Payable</strong></font></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="60%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>2010 (due August 2013)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div>Notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>45,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>44,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In July 2010, the Company issued an unsecured convertible note payable in the amount of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">25,000</font>. The note carries simple interest at a rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 12</font>% per annum and became due and payable on August 1, 2013. The outstanding amounts are convertible into shares of common stock of the Company at conversion prices of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.08</font> per share. This note is currently outstanding and past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">20,811</font> of accrued interest is recorded as of June 30, 2017.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="60%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>2010 (due August 2013)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>25,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>19,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div>Notes payable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>45,811</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>44,323</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

100000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 48px"> <div><font style="FONT-SIZE: 10pt"><strong>6.</strong></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><strong>Promissory Notes</strong></font></div> </td> </tr> </table>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> Year of issuance:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">(a) 2016 (due November 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">(b) 2017 (due May 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">15,314</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">Promissory notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">125,314</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">10,251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">(a) In 2016, the Company issued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">170,000</font> of promissory notes to various outside investors, with simple interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font>% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> note remained outstanding and was past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">449</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">251</font> of accrued interest is recorded as of June 30, 2017 and December 31, 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">(b) In January 2017, the Company issued a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> unsecured promissory note to an outside investor, with a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 120</font> days and a fixed interest charge consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the principal in cash plus 6% of the principal in shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000</font> shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,040</font>, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">822</font> of additional accrued interest has been recorded.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

6800

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <table style="MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both"> Year of issuance:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">(a) 2016 (due November 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">10,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">(b) 2017 (due May 2017)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">15,314</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both">Promissory notes payable, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">125,314</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">10,251</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">(a) In 2016, the Company issued $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">170,000</font> of promissory notes to various outside investors, with simple interest rates ranging from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4</font>% - <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font>% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10,000</font> note remained outstanding and was past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">449</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">251</font> of accrued interest is recorded as of June 30, 2017 and December 31, 2016.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">(b) In January 2017, the Company issued a $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">100,000</font> unsecured promissory note to an outside investor, with a term of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 120</font> days and a fixed interest charge consisting of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the principal in cash plus 6% of the principal in shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, or <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,000</font> shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,040</font>, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">822</font> of additional accrued interest has been recorded.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

1975000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"></td> <td style="TEXT-ALIGN: left; WIDTH: 0.5in"> <div><font style="FONT-SIZE: 10pt"><b>8.</b></font></div> </td> <td style="TEXT-ALIGN: justify"> <div><font style="FONT-SIZE: 10pt"><b>Commitments and Contingencies</b></font></div> </td> </tr> </table>   <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at June 30, 2017 with respect to such matters, including the matter noted below.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company recently received a payment demand from a former consultant to the Company alleging that he is owed approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">192,000</font> for services rendered. The Company has disputed this demand and the resolution of this matter is uncertain. The Company intends to vigorously protect its rights.</font></div> </div> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On March 1, 2017, we entered into a non-binding letter of intent (“LOI”) with VectorVision, Inc., a Delaware corporation (“VectorVision”), whereby the parties set forth an outline of the terms and conditions pursuant to which we would acquire all of the outstanding shares of stock of VectorVision in exchange for a to be determined number of shares of our common stock. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. VectorVision’s patented standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. We believe the acquisition of VectorVision would expand our technical portfolio and further establish our position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The transaction is subject to significant conditions precedent to closing, including, but not limited to, the satisfactory completion of due diligence, the determination of the amount of purchase consideration, the negotiation of definitive transaction documents, the completion of an audit of VectorVision’s financial statements, and other matters, no later than the August 31, 2017 expiration date of the LOI, as amended. No assurances can be provided regarding whether or when we may complete the acquisition of VectorVision. It is possible that we may never consummate this contemplated acquisition of VectorVision or we may complete such acquisition on terms materially different than those described herein.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

192000

449

251

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>June 30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December 31,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2017</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2016</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="60%"> <div>Year of issuance:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>2016 (due September 2016)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div>Accrued interest</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div>Promissory notes payable  related party, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>16,805</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

14000

The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.

112759

1100000

1.00

1100000

1.00

0.06

0.75

The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).

3803980

1052500

1580372

111369

457500

402600

0.88

60000

0.75

51796

0.88

1.35

0.0161

1405000

0.001

90000000

25634751

25046438

0.001

2000000

1705154

1100000

<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0"> <tr style="TEXT-ALIGN: justify; VERTICAL-ALIGN: top"> <td style="WIDTH: 0px"> <div style="CLEAR:both;CLEAR: both"></div> </td> <td style="TEXT-ALIGN: left; WIDTH: 0.25in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <strong><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>9.</strong></font></div> </td> <td style="TEXT-ALIGN: justify; TEXT-INDENT: 0.125in"> <div style="CLEAR:both;CLEAR: both"><font style="FONT-SIZE: 10pt"> <strong>Stockholders’ Deficit</strong></font></div> </td> </tr> </table>   <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Preferred Stock</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Series A</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During 2016, the Company sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,170,000</font> shares of the Company’s Series A Senior Convertible Preferred Stock (the “Series A Preferred Stock”) to various investors. The purchase price of the Series A Preferred Stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share, for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,170,000</font>. In addition, during 2016, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 535,154</font> shares of its Series A Preferred Stock with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">784,888</font> upon conversion of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">535,149</font> of notes payable and accrued interest. The Series A Preferred Stock has a stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and accrues an annual dividend at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8</font>% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share. Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">At the option of each holder, the Series A Preferred Stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.</font> If not converted by September 30, 2019, the preferred stock (including accrued but unpaid dividends) shall automatically and mandatorily convert into shares of common stock at $0.60 per share. Such mandatory conversion shall be subject to either a registration statement having been filed with the Securities and Exchange Commission, including the common stock underlying the Series A Preferred Stock, and being in effect, or all shares of underlying common stock being saleable under Rule 144 pursuant to the Securities Act without regard to volume limitations.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The issuance of the 1,170,000 shares of Series A Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.60</font> per share being less than the market price of the shares of Series A Preferred Stock at the issuance date as determined by an independent  third-party valuation firm. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Preferred Stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">779,586</font> at December 31, 2016, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the issued Series A Preferred Stock exceeded the proceeds from such issuances. The deemed dividend on the Series A Preferred Stock was accreted using the effective interest method from the respective issuance dates through the earliest conversion date of January 1, 2017. The accretion of the deemed dividend for the year ended December 31, 2016 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">760,011</font>. The remaining balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,575</font>, representing the amount allocable to the January 1, 2017 earliest conversion date, was accreted in January 2017.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Sale of the Company’s Series A Preferred Stock was closed on December 31, 2016.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the six months ended June 30, 2017 the Company declared dividends of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">67,646</font> on its Series A Preferred Stock which were satisfied in full through the issuance of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 112,759</font> shares of common stock.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Series B</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">As of June 30, 2017, the Company had sold <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,100,000</font> shares of the Company’s Series B Convertible Preferred Stock (the “Series B Preferred Stock”) to various investors. The purchase price of the Series B Preferred Stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share, for an aggregate purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,100,000</font>. The Series B Preferred Stock has a stated value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.00</font> per share and accrues an annual dividend at the rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6</font>% of the stated value, calculated quarterly, to be paid in shares of common stock at the rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share. Series B Preferred Stock is convertible commencing December 31, 2017, or earlier upon the approval of the Board of Directors, by the holders thereof into common stock at a conversion rate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share. The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). Dividends are payable to holders of record quarterly, on the last business day of each calendar quarter, from the date of issuance, as may be declared by the Board of Directors, and are cumulative. Series B Preferred Stock is senior to all common stock and junior to the Series A Preferred Stock in terms of liquidation preferences.</div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The issuance of the Series B Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, warrants were issued to purchasers of the Series B Preferred Stock who had previously participated in the 2016 Series A Preferred Stock offering. The Company accounted for the beneficial conversion feature, including an allocation of proceeds for the warrants on a relative fair value basis, in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series B Preferred Stock of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">234,840</font> at June 30, 2017, which equals the amount by which the estimated fair value of the common stock issuable upon conversion of the Series B Preferred Stock exceeded the proceeds from such issuances. The deemed dividend on the Series B Preferred Stock is accreted using the effective interest method from the respective issuance dates through the earliest conversion date of December 31, 2017. The accretion of the deemed dividend for the six months ended June 30, 2017 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">65,942</font>.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the six months ended June 30, 2017, the Company declared dividends of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">13,537</font> on its Series B Preferred Stock which were satisfied in full through the issuance of an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 18,054</font> shares of common stock.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock, first to holders of Series A Preferred Stock, then to holders of Series B Preferred Stock, in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full.</div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">500,000</font> of preferred stock was sold of that series, and at least $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> of the related class of preferred stock is still outstanding. This demand registration right and the piggyback registration rights will terminate when all shares of preferred stock have been converted into common stock.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">In the event of a merger or acquisition or change in control of the Company, both classes of preferred stock (including all accrued but unpaid dividends) will be deemed converted into shares of common stock immediately prior to the closing of such a transaction.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Common Stock</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During 2016 and 2015, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 3,459,091</font></font> shares of common stock for services rendered. The aggregate grant date fair value of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,803,980</font>. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,405,000</font> of these shares were restricted shares subject to vesting requirements over <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12</font> months and subject to forfeiture if vesting conditions were not met. As of December 31, 2016, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,052,500</font> of the restricted shares with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,580,372</font> had vested, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 352,500</font> restricted shares with a fair value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">111,369</font> remained to be vested. As of June 30, 2017, all <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1,405,000</font> shares have fully vested.</font></div> <font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During the first six months of 2017, the Company issued <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 457,500</font> shares of common stock to service providers. The aggregate fair value of the stock was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">402,600</font> based on a valuation per share of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> on the date of grant. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 162,500</font> of these shares were restricted shares subject to vesting requirements over 4 months and subject to forfeiture if vesting conditions were not met. As of June 30, 2017, all such shares have fully vested.</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Additional details of the Company’s restricted common stock are as follows:</font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Weighted Average</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Grant Date Fair</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Number</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Value</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="60%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">of Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Per Share</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Non-vested, December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">352,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.13</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Issued</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">162,500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">0.88</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Vested</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">(515,000)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">1.05</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Forfeited</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="60%"> <div style="CLEAR:both;CLEAR: both">Non-vested, June 30, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both">$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><strong><i><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> Warrants</font></i></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">During March 2017, in connection with the Series B Preferred Stock offering discussed above, the Company issued a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 60,000</font> warrants as additional incentive to investors who had previously invested in the Company’s Series A Preferred Stock offering in 2016. These warrants are fully vested, are immediately exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.75</font> per share, and expire between March 6, 2020 and March 8, 2020. The warrants were valued at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">51,796</font>, based upon the Black-Scholes option-pricing model, with a stock price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font>, volatility of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 135</font>%, and an average risk-free interest rate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.61</font>%.</font></div> <strong><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"> </font></strong></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>A summary of the Company’s warrant activity is as follows: </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both" align="center"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN:Left; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: #9eb6ce 0px solid; BORDER-LEFT: #9eb6ce 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: #9eb6ce 0px solid; BORDER-RIGHT: #9eb6ce 0px solid" cellspacing="0" cellpadding="0" align="left"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div style="CLEAR:both;CLEAR: both">Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div style="CLEAR:both;CLEAR: both">December 31, 2016</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">2,923,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div style="CLEAR:both;CLEAR: both">Granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div style="CLEAR:both;CLEAR: both">60,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div style="CLEAR:both;CLEAR: both">Forfeitures</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="72%"> <div style="CLEAR:both;CLEAR: both">Exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">-</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="72%"> <div style="CLEAR:both;CLEAR: both">June 30, 2017, all exercisable</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div style="CLEAR:both;CLEAR: both">2,983,666</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: Times New Roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div style="CLEAR:both;CLEAR: both"> </div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt"></font> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">As of June 30, 2017, the Company had an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,983,666</font> outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.37</font>, weighted average remaining life of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 1.4</font> years and aggregate intrinsic value of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1,293,512</font>, based upon a stock valuation of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.88</font> per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

822

10000

81183

1664

10-Q false 2017-06-30 2017 Q2 Guardion Health Sciences, Inc. 0001642375 --12-31 Smaller Reporting Company 25641551 In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $449 and $251 of accrued interest is recorded as of June 30, 2017 and December 31, 2016. In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $13,040, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $822 of additional accrued interest has been recorded.

EX-101.SCH 6 cik0001642375-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 103 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 104 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 105 - Statement - Condensed Statement of Stockholders' Equity Deficiency link:presentationLink link:definitionLink link:calculationLink 106 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Organization and Business Operations link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Property and Equipment, net link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Convertible Notes Payable link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Promissory Notes link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Promissory Notes - Related Party link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Promissory Notes (Tables) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Promissory Notes - Related Party (Tables) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Organization and Business Operations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Property and Equipment, net (Details Textual) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Convertible Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Convertible Notes Payable (Details Textual) link:presentationLink link:definitionLink link:calculationLink 135 - Disclosure - Promissory Notes (Details) link:presentationLink link:definitionLink link:calculationLink 136 - Disclosure - Promissory Notes (Details Textual) link:presentationLink link:definitionLink link:calculationLink 137 - Disclosure - Promissory Notes - Related Party (Details) link:presentationLink link:definitionLink link:calculationLink 138 - Disclosure - Promissory Notes - Related Party (Details Textual) link:presentationLink link:definitionLink link:calculationLink 139 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 140 - Disclosure - Stockholders' Deficit (Details) link:presentationLink link:definitionLink link:calculationLink 141 - Disclosure - Stockholders' Deficit (Details 1) link:presentationLink link:definitionLink link:calculationLink 142 - Disclosure - Stockholders' Deficit (Details Textual) link:presentationLink link:definitionLink link:calculationLink 143 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 144 - Disclosure - Subsequent Events (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 cik0001642375-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cik0001642375-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cik0001642375-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Statement of Financial Position [Abstract] Statement [Table] Class of Stock [Axis] Class of Stock [Domain] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash Balance at beginning of period Balance at end of period Accounts Receivable, Net, Current Accounts receivable Inventory, Net Inventories Inventory, Net Prepaid Expense and Other Assets, Current Current portion of deposits and prepaid expenses Assets, Current Total current assets Prepaid Expense and Other Assets, Noncurrent Deposits and prepaid expenses, less current portion Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders’ Deficiency Liabilities and Stockholders’ Deficiency Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Deferred Rent Credit, Current Accrued expenses and deferred rent Due to Officers or Stockholders, Current Due to related parties Convertible Notes Payable, Current Convertible notes payable Convertible notes payable - current portion, net Current portion of convertible notes payable - related party Other Notes Payable, Current Promissory notes payable Notes Payable, Related Parties, Current Promissory notes payable related party Liabilities, Current Total current liabilities Commitments and Contingencies Commitments and contingencies Members’ and stockholders’equityDeficit [Abstract] Stockholders’ Deficiency Stockholders’ Deficiency Preferred Stock, Value, Issued Preferred stock Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2015, as reported (unaudited) and as adjusted (unaudited) Common Stock, Value, Issued Common stock, $0.001 par value; 90,000,000 shares authorized; 25,634,751 and 25,046,438 shares issued and outstanding at June 30, 2017 and December 31, 2016 Common stock, $0.0001 par value; 90,000,000 shares authorized; 20,646,396 shares issued and outstanding, as reported (unaudited); 21,701,068 shares issued and outstanding, as adjusted (unaudited) Additional Paid in Capital, Common Stock Additional paid-in capital Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Accumulated deficit Liabilities and Equity, Total Total liabilities and stockholders’ deficiency Total liabilities and stockholders’ deficiency Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Income Statement [Abstract] Revenue, Net Revenue Cost of Goods and Services Sold, Total Cost of goods sold Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development Selling and Marketing Expense, Total Sales and marketing General and Administrative Expense, Total General and administrative Operating Income (Loss), Total Loss from operations Interest and Debt Expense [Abstract] Other expenses: Interest Expense, Total Interest expense Operating Expenses, Total Total operating expenses Net Income (Loss) Attributable to Parent, Total Net loss Net loss Preferred Stock Dividends and Other Adjustments [Abstract] Adjustments related to Series A and Series B convertible preferred stock: Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Members' Equity, Total Members' deficiency; 10,821,827 units outstanding at December 31, 2014 and 2013 Beginning Balance Ending Balance Common Unit, Outstanding Beginning Balance (in shares) Ending Balance (in shares) Stock Issued During Period Value Issued For Consulting Services Issuance of common stock for services Value of stock issued in consulting services. Stock Issued During Period Shares Issued For Consulting Services Issuance of common stock for services (in shares) Number of shares issued in consulting services. Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Amortization of Debt Discount (Premium) Amortization of debt discount Interest Expense, Debt Accrued interest expense included in notes payable Fair Value Adjustment of Warrants Fair value of warrants issued as post-maturity interest Share-based Compensation Stock-based compensation Share-based Compensation, Related Party Transactions Stock-based compensation - related parties The aggregate amount of noncash, equity-based compensation expenses from a related party transactions. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in - Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories, Total Inventories Increase (Decrease) in Prepaid Expense and Other Assets, Total Deposits and prepaid expenses Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in - Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Deferred Liabilities, Total Accrued and deferred rent costs Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities, Continuing Operations, Total Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing Activities Proceeds from Convertible Debt Proceeds from issuance of convertible notes payable Proceeds from Related Party Debt Proceeds from issuance of promissory notes - related party Proceeds from Notes Payable Proceeds from issuance of promissory notes Repayments of Debt Payments on promissory notes Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock Proceeds from (Repayments of) Related Party Debt Increase in due to related parties Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash: Cash and Cash Equivalents, Period Increase (Decrease), Total Net increase Supplemental Cash Flow Elements [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Total Cash paid for - Interest Income Taxes Paid, Net, Total Cash paid for - Income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activities: Stock Issued Issuance of common stock dividends on preferred stock Issuance of common stock upon conversion of accrued management fees Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Fair Value of Warrants Issued In Connection With Promissory and Convertible Notes Payable Fair value of warrants issued in connection with promissory and convertible notes payable The fair value of warrants issued in connection with promissory and convertible notes payable. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Stockholders' Equity Attributable to Parent, Total Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis Of Presentation And Use Of Estimates Policy [Policy Text Block] Disclosure of accounting policy for basis of presentation and use of estimates. Research and Development Expense, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Antidilutive Securities [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share Price Range [Axis] Antidilutive Securities, Name [Domain] Range [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Major Types of Debt and Equity Securities [Axis] Warrant [Member] Major Types of Debt and Equity Securities [Domain] Convertible Debt Securities [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Text Block] Schedule of Inventory, Current [Table Text Block] Inventory, Raw Materials, Net of Reserves Raw materials Inventory, Finished Goods and Work in Process, Net of Reserves, Total Finished goods Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Asset Class [Axis] Members And Stockholders Equity Deficit Total stockholders’ deficiency Total stockholders’ deficiency Total of all stockholders' and members equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Asset Class [Domain] Property, Plant and Equipment [Member] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Type [Domain] Office Equipment [Member] Computer Equipment [Member] Other Machinery and Equipment [Member] Testing equipment [Member] Leasehold Improvements [Member] Furniture and Fixtures [Member] Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Less accumulated depreciation and amortization Disclosure Text Block [Abstract] Debt Instrument [Axis] Debt Instrument, Name [Domain] Convertible Notes Payable [Member] Debt Disclosure [Text Block] Convertible Debt [Table Text Block] Repayments [Axis] Subsequent Event [Table] Long-term Debt, Type [Axis] Repayments [Domain] Due August 2013 [Member] Debt Instrument, Face Amount Interest Payable Accrued interest Accrued interest Subsequent Event Type [Axis] Award Type [Axis] Subsequent Event Type [Domain] Subsequent Event [Member] Stock Issued During Period, Shares, New Issues Stock Issued During Period, Value, New Issues Title of Individual [Axis] Equity Award [Domain] Consultant [Axis] Relationship to Entity [Domain] Legal Entity [Axis] Consultant [Domain] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Axis] Related Party Transaction [Domain] Income Statement Location [Axis] Due to Related Parties, Current Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Class of Warrant or Right [Table] Class of Warrant or Right [Line Items] Class of Warrant or Right, Outstanding Membership Units or Shares, Balance Membership Units or Shares, Balance Membership Units or Shares, Outstanding Warrants Granted Membership Units or Shares, Granted Number of warrants options (or share units) granted during the period. Warrants Cancelled Membership Units or Shares, Forfeitures Number of warrants options (or share units) cancelled during the period. Warrants Exercised Membership Units or Shares, Exercised Number of warrants options (or share units) exercised during the period. Debt Disclosure [Abstract] EX-101.PRE 10 cik0001642375-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2017	Aug. 10, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		25,641,551

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Current assets
Cash	$ 297,536	$ 62,520
Accounts receivable	1,662	1,673
Inventories	108,303	43,999
Current portion of deposits and prepaid expenses	6,576	29,363
Total current assets	414,077	137,555
Deposits and prepaid expenses, less current portion	10,470	10,470
Property and equipment, net	88,188	114,020
Total assets	512,735	262,045
Current liabilities
Accounts payable and accrued liabilities	413,907	356,467
Accrued expenses and deferred rent	14,667	88,290
Due to related parties	169,320	91,483
Convertible notes payable	45,811	44,323
Promissory notes payable	125,314	10,251
Promissory notes payable related party	0	16,805
Total current liabilities	769,019	607,619
Commitments and contingencies
Stockholders’ Deficiency
Common stock, $0.001 par value; 90,000,000 shares authorized; 25,634,751 and 25,046,438 shares issued and outstanding at June 30, 2017 and December 31, 2016	25,635	25,046
Additional paid-in capital	22,056,862	20,277,882
Accumulated deficit	(22,341,586)	(20,650,207)
Total stockholders’ deficiency	(256,284)	(345,574)
Total liabilities and stockholders’ deficiency	512,735	262,045
Series A Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	1,705	1,705
Series B Preferred Stock [Member]
Stockholders’ Deficiency
Preferred stock	$ 1,100	$ 0

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	25,634,751	25,046,438
Common Stock, Shares, Outstanding	25,634,751	25,046,438
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	2,000,000	2,000,000
Preferred Stock, Shares Issued	1,705,154	1,705,154
Preferred Stock, Shares Outstanding	1,705,154	1,705,154
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Preferred Stock, Shares Authorized	2,000,000
Preferred Stock, Shares Issued	1,100,000
Preferred Stock, Shares Outstanding	1,100,000

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
Condensed Statements of Operations - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue	$ 59,977	$ 29,384	$ 115,912	$ 58,518
Cost of goods sold	29,692	12,883	52,326	27,130
Gross profit	30,285	16,501	63,586	31,388
Operating expenses
Research and development	15,530	12,101	25,770	22,273
Sales and marketing	101,598	104,535	178,333	208,114
General and administrative	766,894	893,045	1,365,807	1,517,002
Total operating expenses	884,022	1,009,681	1,569,910	1,747,389
Loss from operations	(853,737)	(993,180)	(1,506,324)	(1,716,001)
Other expenses:
Interest expense	1,924	357,446	18,355	583,830
Total other expenses	1,924	357,446	18,355	583,830
Net loss	(855,661)	(1,350,626)	(1,524,679)	(2,299,831)
Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend	(53,675)	(27,196)	(85,517)	(27,196)
Dividend declared	(45,106)	(1,664)	(81,183)	(1,664)
Net loss attributable to common shareholders	$ (954,442)	$ (1,379,486)	$ (1,691,379)	$ (2,328,691)
Net loss per common share - basic and diluted	$ (0.04)	$ (0.06)	$ (0.07)	$ (0.11)
Weighted average common shares outstanding - basic and diluted	25,470,418	21,315,242	25,287,759	21,299,171

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Statement of Stockholders' Equity Deficiency - 6 months ended Jun. 30, 2017 - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2016	$ (345,574)	$ 1,705	$ 0	$ 25,046	$ 20,277,882	$ (20,650,207)
Beginning Balance (in shares) at Dec. 31, 2016		1,705,154	0	25,046,438
Issuance of common stock for services	513,969	$ 0	$ 0	$ 458	513,511	0
Issuance of common stock for services (in shares)		0	0	457,500
Issuance of preferred stock	1,100,000	$ 0	$ 1,100	$ 0	1,098,900	0
Issuance of preferred stock (in shares)		0	1,100,000	0
Accretion of beneficial conversion feature on preferred stock	0			$ 0	85,517	(85,517)
Dividend on preferred stock	0	$ 0	$ 0	$ 131	81,052	(81,183)
Dividend on preferred stock (in shares)		0	0	130,813
Net loss	(1,524,679)	$ 0	$ 0	$ 0	0	(1,524,679)
Ending Balance at Jun. 30, 2017	$ (256,284)	$ 1,705	$ 1,100	$ 25,635	$ 22,056,862	$ (22,341,586)
Ending Balance (in shares) at Jun. 30, 2017		1,705,154	1,100,000	25,634,751

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows - USD ($)	6 Months Ended
Condensed Statements of Cash Flows - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Operating Activities
Net loss	$ (1,524,679)	$ (2,299,831)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	31,331	18,815
Amortization of debt discount	0	293,821
Accrued interest expense included in notes payable	13,746	40,827
Fair value of warrants issued as post-maturity interest	0	246,578
Stock-based compensation	405,918	378,056
Stock-based compensation - related parties	108,051	534,098
(Increase) decrease in -
Accounts receivable	11	329
Inventories	(64,305)	(3,295)
Deposits and prepaid expenses	22,788	17,358
Increase (decrease) in -
Accounts payable and accrued expenses	57,442	90,648
Accrued and deferred rent costs	(73,624)	(23,839)
Net cash used in operating activities	(1,023,321)	(706,435)
Investing Activities
Purchase of property and equipment	(5,500)	(1,171)
Net cash used in investing activities	(5,500)	(1,171)
Financing Activities
Proceeds from issuance of convertible notes payable	0	136,000
Proceeds from issuance of promissory notes - related party	0	140,000
Proceeds from issuance of promissory notes	100,000	170,000
Payments on promissory notes	(14,000)	(130,000)
Proceeds from issuance of preferred stock	1,100,000	545,000
Increase in due to related parties	77,837	110,300
Net cash provided by financing activities	1,263,837	971,300
Cash:
Net increase	235,016	263,694
Balance at beginning of period	62,520	13,850
Balance at end of period	297,536	277,544
Supplemental disclosure of cash flow information:
Cash paid for - Interest	1,500	0
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock dividends on preferred stock	81,183	1,664
Fair value of warrants issued in connection with promissory and convertible notes payable	0	245,349
Beneficial conversion feature associated with promissory and convertible notes payable	$ 0	$ 70,949

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business Operations

6 Months Ended

Jun. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.	Organization and Business Operations

Organization and Business

Going Concern and Liquidity

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

2.	Summary of Significant Accounting Policies

Basis of Presentation and Use of Estimates

Research and Development Costs

Stock-Based Compensation

	Six Months Ended June 30,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	June 30,
	2017		2016
Warrants		2,983,666		2,873,666
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		4,308,600		908,335
		7,323,516		5,227,812

Recent Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

Inventories

Inventories consisted of the following:

	June 30,		December 31,
	2017		2016
Raw materials	$	106,159	$	40,679
Finished goods		2,144		3,320
	$	108,303	$	43,999

XML 20 R10.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment, net

Property and equipment consisted of the following:

	June 30,		December 31,
	2017		2016
Leasehold improvements	$	98,357	$	98,357
Testing equipment		145,503		145,503
Furniture and fixtures		15,348		15,348
Computer equipment		15,277		15,277
Office equipment		8,193		2,694
		282,678		277,179
Less accumulated depreciation and amortization		(194,490)		(163,159)
	$	88,188	$	114,020

XML 21 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

6 Months Ended

Jun. 30, 2017

Convertible Notes Payable [Member]

Debt Disclosure [Text Block]

Convertible Notes Payable

	June 30,		December 31,
	2017		2016
Year of issuance:
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,811		19,323
Notes payable	$	45,811	$	44,323

XML 22 R12.htm IDEA: XBRL DOCUMENT

Promissory Notes

6 Months Ended

Jun. 30, 2017

Promissory Notes Payable [Member]

Debt Disclosure [Text Block]

6.	Promissory Notes

	June 30,		December 31,
	2017		2016
Year of issuance:
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,314		251
Promissory notes payable, net	$	125,314	$	10,251

XML 23 R13.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party

6 Months Ended

Jun. 30, 2017

Investor [Member]

Debt Disclosure [Text Block]

7.	Promissory Notes – Related Party

	June 30,		December 31,
	2017		2016
Year of issuance:
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

6 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

XML 25 R15.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders’ Deficit

Preferred Stock

Series A

Sale of the Company’s Series A Preferred Stock was closed on December 31, 2016.

Series B

Common Stock

Additional details of the Company’s restricted common stock are as follows:

			Weighted Average
			Grant Date Fair
	Number		Value
	of Shares		Per Share
Non-vested, December 31, 2016		352,500		1.13
Issued		162,500		0.88
Vested		(515,000)		1.05
Forfeited		-		-
Non-vested, June 30, 2017		-	$	-

Warrants

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
June 30, 2017, all exercisable		2,983,666

XML 26 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2017

10.

Related Party Transactions

XML 27 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2017

Subsequent Events [Abstract]

Subsequent Events [Text Block]

11.

Subsequent Events

During July 2017, the Company issued 6,800 shares of fully vested common stock to consultants for services rendered.

During July 2017, the Company repaid a $100,000 unsecured promissory note from a related party investor.

XML 28 R18.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]

Basis of Presentation and Use of Estimates

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Stock-Based Compensation

	Six Months Ended June 30,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	June 30,
	2017		2016
Warrants		2,983,666		2,873,666
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		4,308,600		908,335
		7,323,516		5,227,812

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm using multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Six Months Ended June 30,
	2017			2016
Discount rate		16	%		16	%
Risk free rate		2.48	%		2.27	%
Rate of return		16	%		16	%
Sustainable growth rate		5	%		5	%
Company survival probability		65	%		63	%
Liquidation value	$	0		$	0

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	June 30,
	2017		2016
Warrants		2,983,666		2,873,666
Estimated shares issuable upon conversion of convertible notes payable		31,250		1,445,811
Shares issuable upon conversion of convertible preferred stock		4,308,600		908,335
		7,323,516		5,227,812

XML 30 R20.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended

Jun. 30, 2017

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following:

	June 30,		December 31,
	2017		2016
Raw materials	$	106,159	$	40,679
Finished goods		2,144		3,320
	$	108,303	$	43,999

XML 31 R21.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

6 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following:

	June 30,		December 31,
	2017		2016
Leasehold improvements	$	98,357	$	98,357
Testing equipment		145,503		145,503
Furniture and fixtures		15,348		15,348
Computer equipment		15,277		15,277
Office equipment		8,193		2,694
		282,678		277,179
Less accumulated depreciation and amortization		(194,490)		(163,159)
	$	88,188	$	114,020

XML 32 R22.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Tables)

6 Months Ended

Jun. 30, 2017

Convertible Notes Payable [Member]

Convertible Debt [Table Text Block]

	June 30,		December 31,
	2017		2016
Year of issuance:
2010 (due August 2013)	$	25,000	$	25,000
Accrued interest		20,811		19,323
Notes payable	$	45,811	$	44,323

XML 33 R23.htm IDEA: XBRL DOCUMENT

Promissory Notes (Tables)

6 Months Ended

Jun. 30, 2017

Promissory Notes Payable [Member]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	June 30,		December 31,
	2017		2016
Year of issuance:
(a) 2016 (due November 2016)	$	10,000	$	10,000
(b) 2017 (due May 2017)		100,000		-
Accrued interest		15,314		251
Promissory notes payable, net	$	125,314	$	10,251

XML 34 R24.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Tables)

6 Months Ended

Jun. 30, 2017

Investor [Member]

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	June 30,		December 31,
	2017		2016
Year of issuance:
2016 (due September 2016)	$	-	$	14,000
Accrued interest		-		2,805
Promissory notes payable – related party, net	$	-	$	16,805

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Tables)

6 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

Nonvested Restricted Stock Shares Activity [Table Text Block]

Additional details of the Company’s restricted common stock are as follows:

			Weighted Average
			Grant Date Fair
	Number		Value
	of Shares		Per Share
Non-vested, December 31, 2016		352,500		1.13
Issued		162,500		0.88
Vested		(515,000)		1.05
Forfeited		-		-
Non-vested, June 30, 2017		-	$	-

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2016		2,923,666
Granted		60,000
Forfeitures		-
Exercised		-
June 30, 2017, all exercisable		2,983,666

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R26.htm IDEA: XBRL DOCUMENT

Organization and Business Operations (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total			$ (1,023,321)	$ (706,435)
Stockholders' Equity Attributable to Parent, Total	$ 256,284		256,284
Net Income (Loss) Attributable to Parent, Total	$ (855,661)	$ (1,350,626)	$ (1,524,679)	$ (2,299,831)

XML 37 R27.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount rate	16.00%	16.00%
Risk free rate	2.48%	2.27%
Rate of return	16.00%	16.00%
Sustainable growth rate	5.00%	5.00%
Company survival probability	65.00%	63.00%
Liquidation value	$ 0	$ 0

XML 38 R28.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,323,516	5,227,812
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,308,600	908,335
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	31,250	1,445,811
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,983,666	2,873,666

XML 39 R29.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Research and Development Expense	$ 15,530	$ 12,101	$ 25,770	$ 22,273
Share Price	$ 0.88	$ 1.00	$ 0.88	$ 1.00	$ 1.00

XML 40 R30.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Raw materials	$ 106,159	$ 40,679
Finished goods	2,144	3,320
Inventory, Net	$ 108,303	$ 43,999

XML 41 R31.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross, Total	$ 282,678	$ 277,179
Less accumulated depreciation and amortization	(194,490)	(163,159)
Property, Plant and Equipment, Net, Total	88,188	114,020
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	8,193	2,694
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	15,277	15,277
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	145,503	145,503
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	$ 15,348	$ 15,348

XML 42 R32.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Property and Equipment, net (Details Textual) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Depreciation, Depletion and Amortization, Nonproduction, Total			$ 31,331	$ 18,815
Research and Development Expense	$ 15,530	$ 12,101	25,770	22,273
General and Administrative Expense, Total	$ 766,894	$ 893,045	1,365,807	1,517,002
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total			31,331	18,815
Research and Development Expense			14,650	12,840
General and Administrative Expense, Total			$ 16,681	$ 5,975

XML 43 R33.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details) - Convertible Notes Payable [Member] - Unsecured Notes Payable [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued interest	$ 20,811	$ 19,323
Notes payable	45,811	44,323
Due August 2013 [Member]
Debt Instrument, Face Amount	$ 25,000	$ 25,000

XML 44 R34.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
Convertible Notes Payable (Details Textual) - USD ($)	Jul. 31, 2010	Jun. 30, 2017	Jun. 30, 2016
Proceeds from Convertible Debt		$ 0	$ 136,000
Convertible Notes Payable [Member] \| Unsecured Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Convertible, Conversion Price	$ 0.08
Proceeds from Convertible Debt	$ 25,000
Interest Payable		$ 20,811

XML 45 R35.htm IDEA: XBRL DOCUMENT

Promissory Notes (Details) - Notes Payable, Other Payables [Member] - USD ($)

Jun. 30, 2017

Dec. 31, 2016

Unsecured Promissory Notes [Member]

Accrued interest

$ 15,314

$ 251

Promissory notes payable, net

125,314

10,251

2016 (due November 2016)

Debt Instrument, Face Amount

^[1]

10,000

2017 (due May 2017) [Member]

Debt Instrument, Face Amount

^[2]

$ 100,000

$ 0

[1]

In 2016, the Company issued $170,000 of promissory notes to various outside investors, with simple interest rates ranging from 4% - 9% and a weighted average term at issuance of approximately three months. As of June 30, 2017 and December 31, 2016, a $10,000 note remained outstanding and was past due, and $449 and $251 of accrued interest is recorded as of June 30, 2017 and December 31, 2016.

[2]

In January 2017, the Company issued a $100,000 unsecured promissory note to an outside investor, with a term of 120 days and a fixed interest charge consisting of 6% of the principal in cash plus 6% of the principal in shares of common stock at a price of $0.75 per share, or 8,000 shares. Because the interest charge is fixed and due in full at any repayment date regardless of the stated maturity date, the Company recorded accrued interest of $13,040, representing the total fair value of the charge, at the inception of the note. As of June 30, 2017, this note is past due, and $822 of additional accrued interest has been recorded.

XML 46 R36.htm IDEA: XBRL DOCUMENT

Promissory Notes (Details Textual) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
Promissory Notes (Details Textual) - USD ($)	Jan. 31, 2017	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable		$ 100,000	$ 170,000
Short-term Debt					$ 14,000
2016 Issuances [Member]
Short-term Debt		10,000		$ 10,000
Interest Payable, Current		449		251
2016 Issuances [Member] \| Investor [Member]
Proceeds from Notes Payable				140,000
Notes Payable, Other Payables [Member] \| 2016 Issuances [Member]
Proceeds from Notes Payable				$ 170,000
Notes Payable, Other Payables [Member] \| Minimum [Member] \| 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				4.00%
Notes Payable, Other Payables [Member] \| Maximum [Member] \| 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage				9.00%
Promissory Note [Member] \| Investor [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.75
Interest Payable, Current	$ 13,040	$ 822
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Term	120 days
Short-term Debt, Percentage Bearing Fixed Interest Rate	6.00%
Debt Conversion, Converted Instrument, Shares Issued	8,000

XML 47 R37.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Details) - Investor [Member] - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Accrued interest	$ 0	$ 2,805
Promissory notes payable - related party, net	0	16,805
2016 (due September 2016) [Member] \| Unsecured Debt [Member]
Accrued interest	$ 0	$ 14,000

XML 48 R38.htm IDEA: XBRL DOCUMENT

Promissory Notes - Related Party (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable	$ 100,000	$ 170,000
Short-term Debt				$ 14,000
2016 Issuances [Member]
Short-term Debt	$ 10,000		$ 10,000
Minimum [Member] \| Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			6.00%
Maximum [Member] \| Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate			12.00%
Investor [Member] \| 2016 Issuances [Member]
Proceeds from Notes Payable			$ 140,000

XML 49 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual)	6 Months Ended
Commitments and Contingencies (Details Textual)	Jun. 30, 2017 USD ($)
Loss Contingency, Damages Sought, Value	$ 192,000

XML 50 R40.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2017 $ / shares shares
Number of Shares, Beginning Balance \| shares	352,500
Number of Shares, Issued \| shares	162,500
Number of Shares, Vested \| shares	(515,000)
Number of Shares, Forfeited \| shares	0
Number of Shares, Ending Balance \| shares	0
Weighted Average Grant Date Fair Value Per Share, Beginning Balance \| $ / shares	$ 1.13
Weighted Average Grant Date Fair Value Per Share, Issued \| $ / shares	0.88
Weighted Average Grant Date Fair Value Per Share, Vested \| $ / shares	1.05
Weighted Average Grant Date Fair Value Per Share, Forfeited \| $ / shares	0
Weighted Average Grant Date Fair Value Per Share, Ending Balance \| $ / shares	$ 0

XML 51 R41.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details 1)	6 Months Ended
Stockholders' Deficit (Details 1)	Jun. 30, 2017 shares
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	2,923,666
Membership Units or Shares, Granted	60,000
Membership Units or Shares, Forfeitures	0
Membership Units or Shares, Exercised	0
Membership Units or Shares, Balance	2,983,666

XML 52 R42.htm IDEA: XBRL DOCUMENT

Stockholders' Deficit (Details Textual) - USD ($)	6 Months Ended		12 Months Ended
Stockholders' Deficit (Details Textual) - USD ($)	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016	Jan. 31, 2017	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share	$ 1.00
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.75
Class of Warrant or Right, Outstanding	2,983,666		2,923,666
Warrants Intrinsic Value	$ 1,293,512
Share Price	$ 0.88	$ 1.00			$ 1.00
Accretion of Dividends	$ 65,942		$ 760,011	$ 19,575
Debt Conversion, Original Debt, Amount			535,149
Stock Issued	81,183	$ 1,664
Warrants Issued	$ 60,000
Deemed Dividend			$ 779,586
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.37
Fair Value Assumptions, Expected Volatility Rate	135.00%
Fair Value Assumptions, Risk Free Interest Rate	1.61%
Warrants Weighted Average Remaining Life	1 year 4 months 24 days
Share Price	$ 0.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 51,796
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services	457,500
Share Price	$ 0.88
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	162,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 1,405,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value	$ 402,600
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	0		352,500
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues			3,459,091
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value			$ 111,369
Stock Issued			$ 3,803,980
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number			1,052,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value			$ 1,580,372
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number			1,405,000
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued			535,154
Stock Issued			$ 784,888
Minimum [Member]
Class of Warrant or Right [Line Items]
Accretion of Dividends	$ 250,000
Minimum [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			9 months
Maximum [Member] \| Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period			12 months
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share			$ 1.00
Share Price			$ 1.00
Stock Issued During Period, Shares, New Issues			1,170,000
Stock Issued During Period, Value, New Issues			$ 1,170,000
Preferred Stock, Dividend Rate, Percentage			8.00%
Preferred Stock, Dividends Per Share, Declared	$ 0.60		$ 0.60
Convertible Preferred Stock, Terms of Conversion			The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.
Common Stock Dividends, Shares	112,759
Dividends, Preferred Stock, Stock	$ 67,646
Series A Preferred Stock [Member] \| Minimum [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues	$ 500,000
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Share Price	$ 1.00
Stock Issued During Period, Shares, New Issues	1,100,000
Stock Issued During Period, Value, New Issues	$ 1,100,000
Preferred Stock, Dividend Rate, Percentage	6.00%
Preferred Stock, Dividends Per Share, Declared	$ 0.75
Convertible Preferred Stock, Conversion Price	$ 0.75
Convertible Preferred Stock, Terms of Conversion	The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).
Common Stock Dividends, Shares	18,054
Deemed Dividend	$ 234,840
Series B Preferred Stock [Member] \| Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock	$ 13,537

XML 53 R43.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
Related Party Transactions (Details Textual) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due to Related Parties, Current	$ 169,320	$ 91,483
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments to Employees	50,000	48,500
General and Administrative Expense [Member] \| Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Officers' Compensation	$ 125,000	$ 250,000

XML 54 R44.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Textual) - USD ($)	1 Months Ended	6 Months Ended
Subsequent Events (Details Textual) - USD ($)	Jul. 31, 2017	Jun. 30, 2017
Subsequent Event [Line Items]
Repayments of Related Party Debt	$ 100,000
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		1,100,000
Stock Issued During Period, Value, New Issues		$ 1,100,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services	6,800
Subsequent Event [Member] \| Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	1,975,000
Stock Issued During Period, Value, New Issues	$ 1,975,000

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 99 179 1 true 36 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.guardionhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - Condensed Balance Sheets Sheet http://www.guardionhealth.com/role/CondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 103 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.guardionhealth.com/role/CondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 104 - Statement - Condensed Statements of Operations Sheet http://www.guardionhealth.com/role/CondensedStatementsOfOperations Condensed Statements of Operations Statements 4 false false R5.htm 105 - Statement - Condensed Statement of Stockholders' Equity Deficiency Sheet http://www.guardionhealth.com/role/CondensedStatementOfStockholdersEquityDeficiency Condensed Statement of Stockholders' Equity Deficiency Statements 5 false false R6.htm 106 - Statement - Condensed Statements of Cash Flows Sheet http://www.guardionhealth.com/role/CondensedStatementsOfCashFlows Condensed Statements of Cash Flows Statements 6 false false R7.htm 107 - Disclosure - Organization and Business Operations Sheet http://www.guardionhealth.com/role/OrganizationAndBusinessOperations Organization and Business Operations Notes 7 false false R8.htm 108 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 109 - Disclosure - Inventories Sheet http://www.guardionhealth.com/role/Inventories Inventories Notes 9 false false R10.htm 110 - Disclosure - Property and Equipment, net Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNet Property and Equipment, net Notes 10 false false R11.htm 111 - Disclosure - Convertible Notes Payable Notes http://www.guardionhealth.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 11 false false R12.htm 112 - Disclosure - Promissory Notes Notes http://www.guardionhealth.com/role/PromissoryNotes Promissory Notes Notes 12 false false R13.htm 113 - Disclosure - Promissory Notes - Related Party Notes http://www.guardionhealth.com/role/PromissoryNotesRelatedParty Promissory Notes - Related Party Notes 13 false false R14.htm 114 - Disclosure - Commitments and Contingencies Sheet http://www.guardionhealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 115 - Disclosure - Stockholders' Deficit Sheet http://www.guardionhealth.com/role/StockholdersDeficit Stockholders' Deficit Notes 15 false false R16.htm 116 - Disclosure - Related Party Transactions Sheet http://www.guardionhealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 117 - Disclosure - Subsequent Events Sheet http://www.guardionhealth.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 118 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 119 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 120 - Disclosure - Inventories (Tables) Sheet http://www.guardionhealth.com/role/InventoriesTables Inventories (Tables) Tables http://www.guardionhealth.com/role/Inventories 20 false false R21.htm 121 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://www.guardionhealth.com/role/PropertyAndEquipmentNet 21 false false R22.htm 122 - Disclosure - Convertible Notes Payable (Tables) Notes http://www.guardionhealth.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://www.guardionhealth.com/role/ConvertibleNotesPayable 22 false false R23.htm 123 - Disclosure - Promissory Notes (Tables) Notes http://www.guardionhealth.com/role/PromissoryNotesTables Promissory Notes (Tables) Tables http://www.guardionhealth.com/role/PromissoryNotes 23 false false R24.htm 124 - Disclosure - Promissory Notes - Related Party (Tables) Notes http://www.guardionhealth.com/role/PromissoryNotesRelatedPartyTables Promissory Notes - Related Party (Tables) Tables http://www.guardionhealth.com/role/PromissoryNotesRelatedParty 24 false false R25.htm 125 - Disclosure - Stockholders' Deficit (Tables) Sheet http://www.guardionhealth.com/role/StockholdersDeficitTables Stockholders' Deficit (Tables) Tables http://www.guardionhealth.com/role/StockholdersDeficit 25 false false R26.htm 126 - Disclosure - Organization and Business Operations (Details Textual) Sheet http://www.guardionhealth.com/role/OrganizationAndBusinessOperationsDetailsTextual Organization and Business Operations (Details Textual) Details http://www.guardionhealth.com/role/OrganizationAndBusinessOperations 26 false false R27.htm 127 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 27 false false R28.htm 128 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 28 false false R29.htm 129 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 130 - Disclosure - Inventories (Details) Sheet http://www.guardionhealth.com/role/InventoriesDetails Inventories (Details) Details http://www.guardionhealth.com/role/InventoriesTables 30 false false R31.htm 131 - Disclosure - Property and Equipment, net (Details) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables 31 false false R32.htm 132 - Disclosure - Property and Equipment, net (Details Textual) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetDetailsTextual Property and Equipment, net (Details Textual) Details http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables 32 false false R33.htm 133 - Disclosure - Convertible Notes Payable (Details) Notes http://www.guardionhealth.com/role/ConvertibleNotesPayableDetails Convertible Notes Payable (Details) Details http://www.guardionhealth.com/role/ConvertibleNotesPayableTables 33 false false R34.htm 134 - Disclosure - Convertible Notes Payable (Details Textual) Notes http://www.guardionhealth.com/role/ConvertibleNotesPayableDetailsTextual Convertible Notes Payable (Details Textual) Details http://www.guardionhealth.com/role/ConvertibleNotesPayableTables 34 false false R35.htm 135 - Disclosure - Promissory Notes (Details) Notes http://www.guardionhealth.com/role/PromissoryNotesDetails Promissory Notes (Details) Details http://www.guardionhealth.com/role/PromissoryNotesTables 35 false false R36.htm 136 - Disclosure - Promissory Notes (Details Textual) Notes http://www.guardionhealth.com/role/PromissoryNotesDetailsTextual Promissory Notes (Details Textual) Details http://www.guardionhealth.com/role/PromissoryNotesTables 36 false false R37.htm 137 - Disclosure - Promissory Notes - Related Party (Details) Notes http://www.guardionhealth.com/role/PromissoryNotesRelatedPartyDetails Promissory Notes - Related Party (Details) Details http://www.guardionhealth.com/role/PromissoryNotesRelatedPartyTables 37 false false R38.htm 138 - Disclosure - Promissory Notes - Related Party (Details Textual) Notes http://www.guardionhealth.com/role/PromissoryNotesRelatedPartyDetailsTextual Promissory Notes - Related Party (Details Textual) Details http://www.guardionhealth.com/role/PromissoryNotesRelatedPartyTables 38 false false R39.htm 139 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.guardionhealth.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.guardionhealth.com/role/CommitmentsAndContingencies 39 false false R40.htm 140 - Disclosure - Stockholders' Deficit (Details) Sheet http://www.guardionhealth.com/role/StockholdersDeficitDetails Stockholders' Deficit (Details) Details http://www.guardionhealth.com/role/StockholdersDeficitTables 40 false false R41.htm 141 - Disclosure - Stockholders' Deficit (Details 1) Sheet http://www.guardionhealth.com/role/StockholdersDeficitDetails1 Stockholders' Deficit (Details 1) Details http://www.guardionhealth.com/role/StockholdersDeficitTables 41 false false R42.htm 142 - Disclosure - Stockholders' Deficit (Details Textual) Sheet http://www.guardionhealth.com/role/StockholdersDeficitDetailsTextual Stockholders' Deficit (Details Textual) Details http://www.guardionhealth.com/role/StockholdersDeficitTables 42 false false R43.htm 143 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.guardionhealth.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.guardionhealth.com/role/RelatedPartyTransactions 43 false false R44.htm 144 - Disclosure - Subsequent Events (Details Textual) Sheet http://www.guardionhealth.com/role/SubsequentEventsDetailsTextual Subsequent Events (Details Textual) Details http://www.guardionhealth.com/role/SubsequentEvents 44 false false All Reports Book All Reports cik0001642375-20170630.xml cik0001642375-20170630.xsd cik0001642375-20170630_cal.xml cik0001642375-20170630_def.xml cik0001642375-20170630_lab.xml cik0001642375-20170630_pre.xml true true ZIP 61 0001144204-17-042023-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-17-042023-xbrl.zip M4$L#!!0 ( #U["DN^SCEMGY@ -7&" : 8VEK,# P,38T,C,W-2TR M,#$W,#8S,"YX;6SLO7ESXTB2)_K_FLUWP.9V3U>:44J -S.[:DV94F:K)P^9 MI.J:V6?/RB @**(+!-@X)''6WG=_[A$!( "" $B")$!%6W652.)P]_ K/")^ M_M?__3*WE2?B^9;K_/Q&.U??*,0Q7--R'G]^\^O]Y[/Q&^5___)O_^.O__/L M3/E"'.+I 3&5AZ5RJ0?ZO:<;?_C1_4KW7%7@/YIZ=A$^GG55;:3\/VKW?0_^ M&?^_RO^]^?;_*5=W]\J9\OS\?&["_0&]_]QPY\K96?26C[H/;X#G_.?'VZ_P M3(W_]O+@V=9[_+<"1#O^>\/Z0U55;=CO]D:#G]_,@F#Q_MT[?/9CJ'LF4#0C MNAW,\/GOD!IUV /^V,VVY?R1N@(%P_? ML1_C2U<>_=RCUVJ3R>0=_36^U+?R+H2':N_^\]O7.V-&YOJ9Y?B![A@I6JP" MVK/76[[;[VJCHCO8%=$-)EEXQ,"!7GO/Y)WN&9YKDW?)Q='MAALZ@;=,"\LG MQOFC^_2._TC'XTS5SGI:?%OH>:![Z^[CO^;<:!(K_Q[X 2_OIR\G+\8L_WK\ M)>?YEO-$_"#_%O8;WM1+W^3HEN'GWT-_RGF/;QGY-\ />+F6N3Q8>&NNAU]R M;@C]LT==7\3W3'7_@8XG_R&'I!>[0&O^\ZN@RF'@%2@+_/H&;%A1_HKJ_]ZG MBGU+I@HUA_?!T^E?S/:XCN($UC! MDG\7?VN9^/W4(IY"Z2_)"3_]5WVYNA5[S+O2E&P()[EFED* MP*R] /PN^06)QI%2M>@YR6_1HP1V3.&FX5E/35YN\EM$DH271U]Q&?)GEPE6 MZ_[>TUZ;8+4NV,T^!3L2-';41L&.MA'L:&\:>^'_<$"R3%/;(E 6VX-?$E<= M/Y[_4I=D>JV63&\_DE'[)Q0^^DT*'_T3\G*;"W;/7JYMFBK8U+,H/V2690@V2P^G%IS8E#"[#E]8]TT/O]#IY._(L;CTR)YQ'S M+G"-/[Z1^0/Q0A]K0G%[ 47[)>+']]E_NBA/-W>10V-M3GZL-'J0]Y M^I KEA/4AR3:2/_0#O]PH!@[E/ZA'?[A8/KPR9W/76>]%ES]*P3ZX:J%Z\!' M_T0T(9^MZ+(5H9RV#ER8IH59IV[?Z)9Y[7S2%U:@VU(?HLL*!73:NG%+ MUR MB'FE>X[E//I2*:++\B5S8MJ0OW8IHT;#HD:35VG7J) ,.NT(.BU4+1FSFAJS MFJQ,F4*:#''-"G''**;*&-6.&'4,W9!!IJE!YC [+/)3#UEN;VZYO0$2!^#'='V^?@%","T[#*PGDHCWZL6P0Y.8GSUWCL8?@C^@ M#XJFT#?$NYOI'OFXS'] N_5TKT))G3]^7S9*,B"7>E6IXE+%V^_%,]7<'].I M91",C@MD6M3G&\^%-P3+&QMR+QY"Z44?EQA;VZV7E9B++LX5THG5=3/;GZ1> MM$HO]KLM+KTZ#-Z:>%(S"C5CC9A.VV=(W6B=;AS,;_P(9L3[IALSRR'>4A21 M5)+\=5U'@/BS?%5[0^3JP++W6>R*HSU&KH)&>DUT?109%=,!21BBP5^=@>.<;J5@6L M;G57A<;?I"(?19&C7W/&XDBS;W4;$'5UOR#J4M.EIM?MI#,JV]BT6:JL5-E# MXY6(XJ;[9/C?OE3:,J4M$9U4VSW.ZZ3:2K5MPRPNXVTO0XAO3Y0C?&UY@7I+ M/6^?YFY8&UZ58KUZNQ<#.@7'*S58:G#K?? W?8E_2N7=5GE3 GS=>GM(SROU M5NIM\_UM?L?XK:=L]\_N_=FTM3!E%S8L;@C%\LQQK'LY%U;_5G4>RB_>6EG+,2D<\?,G[ M4X/\BNWR& V*ONDOTL!.WL#$098&=E #>TVV()6BL+:B<:48_7[M/!$_<+V4 MVR4VY%#F#>1?RWM/=WR=]K+V/R[%7ZA_O?'7[KK=$SW)J<]4BCYK6HCPY MU.Q,*P]*XFW3@WNL8HMV@(.*4J&E0C?]9*6VQTUXJ6+Y'5D$&ZSW[&@QKV2! M?I_JNL?Z:8XNO,;] H>L^4OSD^8GS>\X2\6[&9,TCU-URU(O6J47!U_JW#$( MOZ;26K,C^%QC(H4+H*\D"ZTQVSKLBJ74W^+U1:F_Q]+?:@N"4G]E M1^*V="1NASI5T*-7V9M1*E*E!3=AP<%ZPB&#H&'8.L@MM6;&?V.5SM?8!#LE M@43+\H56;[25_;?WIO.%RU6E!PS0[4S@OTNC7J)9UJ\)!BMYK M4CU(=>:N(_.\#(!)1B@RR:M9A4[4I]2O7^WV;*]&FPOJAU*;96'P:!/P6^(' MGF4$>2V\GW7/;'_9.L-&L@*9P[C,[G.V/T@5.8Z*'&,+E!SKHX_UP; ?],] M3\\TR[$O1 C M#*PG\F,ZM0R2VNIV;P4V?'_MF+@N$>HVG?%$0[QX&_'O##G,+F$8=#Q 53'QU#1TW@[5; PN9BBZJ)*1Z9TNYHR7,U=:/MK22VJVD MO>HMU6@_Q27I;*6SE46KO5A)>]5;JM%^8O8V_1O:JT5[Z,CP*B-V6HE>#?9F MJY O&ZU((T&11C'VR%WXX)-_A;B:]D32Y9G,3^TOPJYE:,T%QU:?S?MFC?;6 M-VL7/W0W<[W@_F1.I*QA1WJC&KS1UMNMI2/;P9%M14-+MVJWP*EN<+*[W7I< MR-2QS_8WV7UFUE1?TUG^5IZ=/^;"J\01:3Z.2(M\C02KE&"5K?&/H6,Q+?9G MND>R"C4GNA]ZY!?.!;TD>ESTF_@*?-J:Y_]Z=[GFX9;O]KO:Z#U& M?[]# C-OH:5YDA4GWOH=5,_382RS"ER9-%'@V2?FO/"2.*#23O$KRT2=?>?J M0Z-?!4&E\_OH_S\ZN;#KS4>X(-:FS,W9I7-;6_=F%8^)_ M<(OZDVX3W)T>?-(];VDYC__0[9 H7&%OR73%R;ZA-']&@S5_U]XH^')Z':J9 M8A+#FNNV__,;](9G:<-A-J"QZX6[$K9%AOX2X46\[XM#! M.P%&'5)=4H-B8M1Q3Q7($5^QV>O7R&)8^/I^;S*95'O[C4<6NF7RE7?0.EJ> MN_!]$OB;:L^H6,D'(\$F*[RW%E+7R&]ND6>SU:R+9 MA3PH6-[8D!'"31@P%AB(-W%F6K'?'X^U\5@D=/TK=R-OG1Q+/#_815?=CCXF MWNJ"*G;[ ZT[ZJW81]5WKN.^V-=WAUVU7_Y.'@_YN@ONO#(,+R3F5TM_L&PK ML,C&WDHK]O=]K3=11ZLAN0()M5*_3JS%(: W&/:']5!_R4O]M[@P /^U-D[+ MM.+ H/6'(JEKW[<#8>O2VN)X,1YW)^HVA(7DWN6[I_P?'ETCF;FV"9\V%5VW M)&P,)SW1=Y2_N0Y:UTFS.%Y,M/ZXMPNI:[86;2S2XFC1'XPU39C,%+YT5Q+7 M2;(X8O3[O6YO6Q)W$C=XO Q&DY43(XTAT,Q9B:?_]N5QT,QZF9>>F[ZZ!VC1A[Q2&AJW9'(X@+NU![2P+=4CKMQ!BL"A;O>!1'![.NMU>7QN,A8$O?WD=Y*X3;G&$..NJPP'DPJ-= MR!4L';(<,:PP;(GJLBV.$]EDN>R]N].Y3JC%P2*;8%>E,[VVP98)\N_86&F+ MP\@9>,SNN/_7=QM34"/IZV1=''7.>OW!8+0+Z=$HTU$)_>!5::->T"29GBKV1.-!+9RZ&Q'C:V I!-L5%27M-4M7XV MZD'R3K%1LNBRE]%886/WT2B.HIL-Q9UN$_^6/!$G)"N5POP]/6EB2I9GM,%$ M$U+0S.NVHV8H4)/Q)\5!;S >:./*Q'QR_>#'](OKFC0>$N_),HA_!R%QL%,RB.43VM)Y;L"XBX)3[1/0,7G"]!Z6R7ELKY*L3&LAF4K,P/1N*2 M1^&[ZR"T0'[%P:/;[8K+R1L1>D=L&Z9:<.TWW?N#!/#WUN(LBPWC7D\@<_V; M=Z:Q0)(ETR=UK(F)Q9%@ MG;R*:8,4> ?;&Y:4RK1!MS\<"1XA];IM:"D03TGMJ]N=3,8]K2(M44'WAGAT M$^Q'W;<,%*5EAP'9?#(PS'AS87NM0&<7Z%3/Q2A90D<]9!<(=5R=;'%9D91^,% Q1R=QHI$V&.S*27PN*NRQE4*2NYPN@;/,! M*=G6IFGCWKJR5#$I>V"C8#C*-CX/^_5PD8HW%T^Z96--^]X5EF+YT@NUL\W' MHRP8#R=:;VTP+B=H/_P4#$Q90.]UQ\!2;?P4UR'[Y?(OJ?=-)N+VXIV*HOUR MX95NP1[WZR^*5A!2R6Z+R7#2W6M1M%QTXY+UJ>YXW*NW*%HNMG%Q\.NIW?%@ MQZ)H!<&4K @-!^)TMJ:B: 79E$S9!H/>(8JB%>17$FFZFBB__11%*XBS[.R- M-IB,]UH4K2#)DN*=VA^(>U_V512M(,SBF# :#L>3_H%JHA7$6APTQI->:JM. MS271"M(L#A[C<5_M=FNLB)9+;%(2*U1U,ASGU?BVKXB6BVE2LNMN/.B->J.: M"Z(59%6RNVXRZ6GCO(+VMO70"I(J"1T3L6Z\4SFT@GB*HT-O,.J+.V3K*(=6 M$%!),,@54 W5T KB*@X!Z\2U?36T@K"*G3W8W6 XK%J K$)*@72*/?F9UANH M0W'[08W%T J"FFQ0#.T?J!A:+E3PYAO0/3QN-;1\%""3JU(.[8_4OKB!ID'E MT"I#UJU2#^WA0D6W2?70*L-7L@&\-T34F:,71*L,4LD>AV941*L,27&X[ \T M=7CTDFB5 2F97S6D)EIE1$IB\F30[XN6?]2::)61*0WLHTE_O"ZP;\X0/QNP MX9D/32W9E!$=1,A]S=8T;-?#.PV#4'*^*GU,K2:RUYS1VI:%DDV"*T?$:N(B M>Q9J6_(W/H152#]3B5_A@4+@WK<2]:HD5J!)_=Y8K"3G4)H?B2EQ""T)@2[T MX+(;BDY&-WNSKS^[WB?7\4,;)]!157KC)26M!!MBH/4FPTDV-&])W<%9K6.D MRP+^N+7"J=DIE6S2APDI[A]IJ:SJ::_;.-P2[!(-!7_ES\9JDC4@?BJ8_E(''I>'/$E$/0% MX8$_$ST(/?+#2=<)-G>-):@S*[QM1]>A>:QCY(N3T+8*IF;'69R YFX?;8F@ MZG*DY'K]T1Q'=9?DC'V5J951V&T7FLN M@4$::^J@VPBV:[+-,B EOMEZ;PRS1.! &MVKL&8'&C#6*G/,R-_Y[%,=O!4O MVJDU[ XXB/U5AJ.HF8VZ[*G6@VLE-?*UL,!E&]PYT%0==?IZE7@C2,&:R*Y9 M@4OVQZ^@_M7$15WZ6[*^M@JL5\)FG6VGI]XUJ*_=C2 MA=2ZE*0$OZO%*ZEUJ="@PN;?/2^E'D!.-6A2A6)$VY:T\\UZ#J%="6MN1Y^_IQ70-:@NZWOP)X7:-3 @58QL!^W$H-;&VX M&ZB26XDD<4D6'CQ-QS(TGGJ?NUY@_3?]N/GR= G28$_KB6!U!:_>G*P-MJ)2_ T/;3T$EY9/F\#!0,RM<+Z%1$OWP51^>5W4%DFVI/'@I#?N M:CN0G#D@CG=L(=(2$-K>J.!,.KYR>ZJ*1%>\>--7Q]W1AE09'M'Q-_;?:V>U MP_$6PBM#IM5$(LLIJ)'J N&.2G!K>]U)W61''92M;79,E^ "#OL]=5!$L/#R M.B@MDFQQ; +!UD<$+[C/[K.-L-1%L'5;J_734.Z[$#@0=@M&,(2Y,.S$5B2N+.G M7F[!_'!^Y]^[%\:_0LLC:SN-;SZ0)?B)@T&JF55E0FIGH6APROIQB8#.V[.P M9DPQ^?#W86(EZ(UGZ:'9C;J#\%HTA&491FH,Z^45'F,08OJ?/7?^*>G(O-VT ML 0C,M6-;.UK=Z>P2-0ENS=Z0U7=CLPUP_+9!E'7*'$)@'96J347Z M#L)MT;@59Q$3[$A6[@^V9!8?!;X1_X/^\4FWT8>RY95LOK+%0)9 '_<&( UA MR\H&Q.R!D8(Q*@&]!(44L8R[+^BX,,Y27;-'OC@5I&>.;E M.=FU.R?W^@MV+;7,;=HK:B5(F:DF+]FW;4U/T8!7/K103L^6([J6M#+HL-&@ M7ZJ+)4/Z6;<\^L.%^<_0#S!K^C']#>Z 5&H+AUZ"J2E(L_#%=5!9-.8EY>G^ M<# :;TEJ!()(3-P@3AQ_RR64$L#-OCJ8I%I_YKYV)^**!%@@]Q])&2KE".+S[D",@"DKX*U;$34'AE;/R;=+(#G"F1B M7YVL(O9LQ5A>9BGVLMYX5+IJ&?2#NC:E%5^\(X%%TBV9H8ZV(_"6+/ALEJU[ M;2&Y$ICG?HJN[/NVI*=(4"6+JCVU$D%I-8T]<.)WV2:A:P=R7X=0]?S-"C!9 MGEN^[WI+C(3)9&='[=P0A*!6J6179U'-/U+4:T)%-(%>_$5VU! M1H% 2U [*](@!B0QO&\7=$I@.-<$PNQ[:Z"Q2&XE$;N_/F)O0JBHNRG49L?D MFUKAQ^U0@;I:26PO2HNJT[57[HH&J 1_LS_8,W-B[EĶ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

7L2SC1Z95"0P '.D$ !X M ( !S3,! &-I:S P,#$V-#(S-S4M,C Q-S V,S!?<')E+GAM;%!+ 4!08 !@ & , ! !+=P$ ! end